🏷

Classifications

Harrison's Part

ICIMD (Inherited Metabolic Disorders)

🔗

Mappings

ICD-10-CM

ICD10CM:E83.00 Disorder of copper metabolism, unspecified

ICD-10-CM E83.00 is the closest code for Menkes disease as a copper metabolism disorder.

👪

Inheritance

1

X-linked recessive inheritance

Menkes disease is inherited as an X-linked recessive disorder caused by ATP7A variants, with classic disease occurring predominantly in hemizygous males.

Show evidence (1 reference)

PMID:19888294 SUPPORT Human Clinical

"MD is inherited as an X-linked recessive trait, and as expected the vast majority of patients are males."

Supports the canonical X-linked recessive inheritance pattern of Menkes disease.

◆

Subtypes

4

Classical Menkes disease

ATP7A hgnc:869

Severe classical presentation with early-onset neurodegeneration, early seizures, and high mortality; truncating ATP7A variants are frequently associated with this subtype.

Show evidence (1 reference)

DOI:10.1002/jimd.12590 SUPPORT Human Clinical

"Early seizures are specific for classical Menkes disease (CMD), that is characterized by early‐onset neurodegenerative disease with high mortality rates."

Defines the severe classical subtype and its early seizure/neurodegenerative phenotype.

Atypical Menkes disease

ATP7A hgnc:869

Attenuated Menkes presentation with better survival than classical disease; ataxia is a distinguishing indicator in systematic subtype definitions.

Show evidence (1 reference)

DOI:10.1002/jimd.12590 SUPPORT Human Clinical

"Ataxia is an independent indicator for atypical Menkes disease, that shows better survival rates than CMD."

Defines atypical Menkes disease as an attenuated ATP7A-related subtype.

Occipital horn syndrome MONDO:0010572

ATP7A hgnc:869

Milder allelic variant of ATP7A deficiency with residual copper transport function. Characterized by connective tissue abnormalities including pathognomonic occipital exostoses, joint laxity, and bladder diverticula, with relatively mild or absent neurodegeneration. Affected individuals typically survive into adulthood.

Show evidence (2 references)

PMID:32528851 SUPPORT Other

"Occipital horn syndrome and ATP7A-related distal motor neuropathy are allelic variants of Menkes disease that have less distinctive clincal and biochemical signs"

Identifies occipital horn syndrome as an allelic variant of Menkes disease with milder presentation.

DOI:10.1002/jimd.12590 SUPPORT Human Clinical

"Bony exostoses, radial head dislocations, herniations and dental abnormalities are specific for occipital horn syndrome (OHS) that may further present with developmental delay and connective tissue manifestations."

Adds systematic-review support for the distinguishing occipital horn syndrome phenotype.

ATP7A-related distal motor neuropathy MONDO:0010338

ATP7A hgnc:869

Mildest allelic variant caused by specific ATP7A missense mutations that selectively impair motor neuron function. Presents with progressive distal muscle weakness and atrophy without copper metabolism abnormalities.

Show evidence (3 references)

PMID:32528851 SUPPORT Other

"Occipital horn syndrome and ATP7A-related distal motor neuropathy are allelic variants of Menkes disease that have less distinctive clincal and biochemical signs"

Identifies ATP7A-related distal motor neuropathy as a milder allelic variant.

CGGV:assertion_ec7c42f3-3cad-4020-aa75-cf103c5381ba-2023-01-10T170000.000Z SUPPORT Other

ClinGen's Charcot-Marie-Tooth GCEP curates this subtype as its own ATP7A gene-disease entity, at Moderate rather than Definitive classification.

CGGV:assertion_ec7c42f3-3cad-4020-aa75-cf103c5381ba-2023-01-10T170000.000Z SUPPORT REVIEW SYNTHESIS Human Clinical

"These patients present during adulthood with progressive distal muscle weakness and atrophy without clinical or biochemical characteristics of systemic copper deficiency."

Supports this subtype's defining feature: an ATP7A phenotype that spares the systemic copper abnormalities of Menkes disease and occipital horn syndrome.

⚙

Pathophysiology

9

ATP7A-mediated copper export failure

ATP7A dysfunction impairs copper movement from the cytosol into the secretory pathway and prevents directional copper export across polarized epithelial barriers. The result is low circulating copper availability with copper retention in intestinal and renal epithelia and inadequate delivery to peripheral tissues and the brain.

enterocyte CL:0000584 epithelial cell of proximal tubule CL:0002306

ATP7A hgnc:869

copper ion transport GO:0006825 ↓ DECREASED

P-type monovalent copper transporter activity GO:0140581 ↓ DECREASED

Golgi apparatus GO:0005794

small intestine UBERON:0002108 kidney UBERON:0002113

Animal models

Brindled mouse (Atp7a Mo-br) Mouse recapitulates A mutant Atp7a allele reproduces the failure to deliver copper through the secretory pathway, assayed in vascular tissue and cultured fibroblasts.

Downstream

Systemic copper deficiency Failed epithelial copper export lowers circulating copper and ceruloplasmin availability.

Brain copper deficiency Inadequate copper transfer across brain barriers limits neuronal copper delivery during development.

Mitochondrial redox imbalance from copper accumulation ATP7A inactivation can also cause paradoxical intracellular copper accumulation and mitochondrial redox injury.

Show evidence (2 references)

PMID:19888294 SUPPORT Human Clinical

"ATP7A is an energy dependent transmembrane protein, which is involved in the delivery of copper to the secreted copper enzymes and in the export of surplus copper from cells."

Supports ATP7A as the central mediator of intracellular copper delivery and cellular copper efflux.

PMID:27226607 SUPPORT In Vitro

"In cells, ATP7A inactivation disrupts copper transport from the cytosol into the secretory pathway."

Demonstrates that ATP7A loss directly disrupts secretory-pathway copper trafficking.

Systemic copper deficiency

Failed ATP7A-dependent epithelial copper export causes low circulating copper and ceruloplasmin. Systemic copper deficiency limits copper delivery to secretory-pathway cuproenzymes in peripheral tissues.

copper ion homeostasis GO:0055070 ⚠ ABNORMAL

blood plasma UBERON:0001969

Downstream

Serum copper Reduced systemic copper availability is measured clinically as low serum copper.

Serum ceruloplasmin Inadequate copper availability reduces circulating ceruloplasmin.

Lysyl oxidase deficiency and connective tissue fragility Peripheral copper deficiency reduces activity of the copper-dependent connective-tissue enzyme lysyl oxidase.

Hair-shaft keratinization and pigmentation enzyme dysfunction Inadequate copper delivery to hair-shaft and pigment enzymes causes the characteristic kinky and hypopigmented hair phenotype.

Show evidence (1 reference)

PMID:22695177 SUPPORT Human Clinical

"Affected individuals manifest low copper and ceruloplasmin levels in plasma or serum, as well as in cerebrospinal fluid."

Supports systemic copper and ceruloplasmin deficiency as a core biochemical state downstream of ATP7A dysfunction.

Brain copper deficiency

ATP7A-dependent copper transfer across brain barriers is inadequate, limiting copper availability to developing neurons and CNS cuproenzymes during the brief presymptomatic neonatal window.

neuron CL:0000540

copper ion transport GO:0006825 ↓ DECREASED

brain UBERON:0000955

Downstream

Cuproenzyme deficiency and neurodevelopmental injury Brain copper deficiency impairs copper-dependent enzymes needed for catecholamine synthesis and mitochondrial energy metabolism.

Show evidence (1 reference)

PMID:24054147 SUPPORT Human Clinical

"Both conditions are linked to a biochemical phenotype (low copper levels in the blood and a copper deficiency in the brain) that denotes abnormal copper metabolism."

Supports brain copper deficiency as a core biochemical mechanism in Menkes disease.

Cuproenzyme deficiency and neurodevelopmental injury

Brain copper deficiency compromises copper-dependent enzymes, especially dopamine-beta-hydroxylase and cytochrome c oxidase. This causes abnormal catecholamine biosynthesis, impaired oxidative phosphorylation, and progressive neurodevelopmental injury with seizures, hypotonia, and brain atrophy.

neuron CL:0000540

catecholamine biosynthetic process GO:0042423 ↓ DECREASED oxidative phosphorylation GO:0006119 ↓ DECREASED

dopamine beta-monooxygenase (dopamine-beta-hydroxylase) activity GO:0004500 ↓ DECREASED cytochrome-c oxidase activity GO:0004129 ↓ DECREASED

mitochondrion GO:0005739

brain UBERON:0000955

Animal models

Brindled mouse (Atp7a Mo-br) Mouse partially recapitulates Demonstrates cuproenzyme inactivation downstream of ATP7A loss, with the expected oxidative consequence when the cuproenzyme is an antioxidant.

Viable brindled mouse (Atp7a Mo-vbr) Mouse partially recapitulates Reduced cytochrome oxidase activity in brain is the cuproenzyme deficit that this node names, measured directly in the tissue where Menkes disease causes neurodegeneration.

Downstream

Seizures Neuronal copper deficiency lowers seizure threshold and contributes to epileptic manifestations.

Neurodevelopmental delay Impaired energy metabolism and catecholamine synthesis disrupt normal brain growth and development.

Cerebral atrophy Impaired copper-dependent neuronal metabolism contributes to irreversible brain atrophy.

Hypotonia Neurologic injury from cuproenzyme deficiency manifests clinically as hypotonia.

Failure to thrive Early neurologic dysfunction and systemic copper deficiency contribute to poor growth.

Plasma DOPA:DHPG ratio Dopamine-beta-hydroxylase deficiency increases diagnostic catecholamine metabolite ratios.

Show evidence (3 references)

PMID:18256395 SUPPORT Human Clinical

"Exploiting the deficiency of a copper enzyme, dopamine-beta-hydroxylase, we prospectively evaluated the diagnostic usefulness of plasma neurochemical levels, assessed the clinical effect of early detection, and investigated the molecular bases for treatment outcomes."

Supports dopamine-beta-hydroxylase deficiency as a measurable biochemical consequence of Menkes disease.

PMID:32381719 SUPPORT Model Organism

"Here we report that the small molecule elesclomol escorted copper to the mitochondria and increased cytochrome c oxidase levels in the brain."

The study's own in-vivo result: restoring mitochondrial copper raises cytochrome c oxidase in Menkes-model brain, grounding the reduced cytochrome-c-oxidase-activity and oxidative-phosphorylation annotations on this node from the intervention rather than from background.

PMID:32714836 SUPPORT Human Clinical

"At birth, affected Menkes infants appear healthy and typically develop normally for 6 to 10 weeks before seizures, failure to thrive, irreversible brain atrophy, and stalled neurodevelopment ensue."

Connects early copper-handling defects to the characteristic neurologic decline and brain atrophy seen in infants.

Mitochondrial redox imbalance from copper accumulation

In cells lacking functional ATP7A, copper accumulates in mitochondria and disrupts glutathione-based redox buffering. This renders cells highly sensitive to oxidative stress and contributes to tissue injury, particularly in renal epithelia where copper paradoxically accumulates.

epithelial cell of proximal tubule CL:0002306

cellular response to oxidative stress GO:0034599 ↑ INCREASED

mitochondrion GO:0005739

kidney UBERON:0002113

Show evidence (2 references)

PMID:27226607 SUPPORT In Vitro

"Redox misbalance does not significantly affect mitochondrion morphology or the activity of respiratory complex IV but markedly increases cell sensitivity to even mild glutathione depletion, resulting in loss of cell viability."

Demonstrates that ATP7A loss causes mitochondrial redox imbalance and increased sensitivity to glutathione depletion.

PMID:27226607 SUPPORT In Vitro

"Mitochondrial redox misbalance could significantly contribute to pathologies associated with ATP7A inactivation in tissues with paradoxical accumulation of copper (i.e. renal epithelia)."

Identifies renal epithelia as a key tissue where mitochondrial redox imbalance contributes to Menkes pathology.

Lysyl oxidase deficiency and connective tissue fragility

Copper deficiency reduces lysyl oxidase activity, weakening collagen and elastin cross-linking in connective tissues and vessel walls. This produces tissue laxity, vascular tortuosity and phlebectasia, hernias, and skeletal fragility.

extracellular matrix organization GO:0030198 ↓ DECREASED

lysyl oxidase (protein-lysine 6-oxidase) activity GO:0004720 ↓ DECREASED

skin UBERON:0002097 blood vessel UBERON:0001981

Downstream

Vascular tortuosity and phlebectasia Defective extracellular-matrix cross-linking weakens vessel walls and alters vascular architecture.

Connective tissue laxity Weak collagen and elastin cross-linking contributes to hernias, skin laxity, and skeletal complications.

Show evidence (1 reference)

PMID:32293788 SUPPORT Human Clinical

"This feature and other connective tissue abnormalities appear to be consequences of deficient activity of lysyl oxidase, a copper-dependent enzyme."

Directly links connective-tissue manifestations in Menkes disease to lysyl oxidase deficiency.

Vascular tortuosity and phlebectasia

Weak elastin and collagen cross-linking in vessel walls leads to tortuous intracranial arteries and benign internal jugular vein phlebectasia.

extracellular matrix organization GO:0030198 ↓ DECREASED

blood vessel UBERON:0001981

Downstream

Arterial tortuosity Vessel-wall matrix weakness produces tortuous intracranial arteries.

Internal jugular vein phlebectasia Venous wall weakness produces fusiform internal jugular vein dilatation.

Show evidence (1 reference)

PMID:32293788 SUPPORT Human Clinical

"We previously identified internal jugular vein phlebectasia (IJP) in four Menkes disease subjects. This feature and other connective tissue abnormalities appear to be consequences of deficient activity of lysyl oxidase, a copper-dependent enzyme."

Supports vascular phlebectasia as a downstream vascular-wall manifestation of lysyl oxidase deficiency.

Connective tissue laxity

Reduced extracellular-matrix cross-linking weakens skin, bladder wall, cranial sutures, bones, and bridging vessels, producing the connective tissue phenotype branch of Menkes disease.

extracellular matrix organization GO:0030198 ↓ DECREASED

skin UBERON:0002097

Downstream

Cutis laxa Defective collagen and elastin cross-linking causes loose, redundant, wrinkled skin.

Bladder diverticulum Weak bladder-wall connective tissue predisposes to diverticula.

Wormian bones Skeletal connective-tissue and mineralization abnormalities include wormian bones.

Subdural hemorrhage Fragile connective tissue and vessels predispose to subdural hemorrhage.

Show evidence (1 reference)

PMID:32293788 SUPPORT Human Clinical

"This feature and other connective tissue abnormalities appear to be consequences of deficient activity of lysyl oxidase, a copper-dependent enzyme."

Supports generalized connective-tissue laxity as a downstream manifestation of lysyl oxidase deficiency.

Hair-shaft keratinization and pigmentation enzyme dysfunction

Copper-dependent hair and pigment biology is disrupted, producing brittle twisted hair shafts and hair hypopigmentation. Reduced activity of the copper-dependent enzyme tyrosinase impairs melanin biosynthesis, while defective disulfide cross-linking weakens the keratinized hair shaft.

melanin biosynthetic process GO:0042438 ↓ DECREASED

tyrosinase activity GO:0004503 ↓ DECREASED

hair follicle UBERON:0002073

Downstream

Pili torti Hair-shaft structural disruption produces twisted, brittle pili torti.

Fair hair Impaired pigment enzyme activity produces hypopigmented fair hair.

Show evidence (2 references)

PMID:19888294 SUPPORT Human Clinical

"Progressive neurodegeneration and connective tissue disturbances, together with the peculiar 'kinky' hair are the main manifestations."

Supports kinky hair as a core Menkes manifestation downstream of copper-transport disruption.

PMID:18650808 SUPPORT In Vitro

"Copper is supplied to melanosomes by ATP7A"

Establishes that ATP7A supplies the copper that activates the pigment-cell cuproenzyme tyrosinase in melanosomes, grounding the reduced tyrosinase-activity and melanin-biosynthesis annotations for the hypopigmentation branch.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

13

Blood 1

Subdural hemorrhage HP:0100309

Frequency band dropped: the sole evidence is a single case report, which cannot establish a population frequency. Orphanet (ORPHA:565) carries no HP:0100309 row; the parent term intracranial hemorrhage (HP:0002170) is classed Very frequent.

Show evidence (1 reference)

PMID:12483361 SUPPORT Human Clinical

"We present a case of Menkes disease complicated by progressive macrocephaly following the development of massive subdural haematomas."

Documents subdural haematomas as a specific complication of Menkes disease that can mimic non-accidental injury.

Cardiovascular 2

Arterial tortuosity HP:0005116

Frequency band dropped: the cited evidence lists tortuous intracranial arteries as a "classic radiographic finding" but gives no quantitative or frequency data. Orphanet (ORPHA:565) carries no HP:0005116 row; the related abnormality of the carotid arteries (HP:0005344) and arterial stenosis (HP:0100545) are classed Frequent.

Show evidence (1 reference)

PMID:31198482 SUPPORT Human Clinical

"The classic radiographic findings seen in Menke's disease have been documented and include wormian bones, diaphyseal and metaphyseal bone fractures, subdural hematomas, and tortuous intracranial arteries"

Documents tortuous intracranial arteries as a classic radiographic finding in Menkes disease.

Internal jugular vein phlebectasia OCCASIONAL Abnormal venous morphology HP:0002624

Show evidence (1 reference)

PMID:32293788 SUPPORT Human Clinical

"Our prospective results suggest that IJP occurs in approximately 14% (9/66) of Menkes disease patients and appears to be clinically benign with no specific medical or surgical actionability."

Documents the frequency and clinical significance of internal jugular vein phlebectasia in Menkes disease.

Genitourinary 1

Bladder diverticulum OCCASIONAL HP:0000015

Show evidence (2 references)

PMID:406641 SUPPORT Human Clinical

"Multiple unusual diverticula of the bladder were observed in 3 of 4 children with Menkes' syndrome."

Documents bladder diverticula as a urological finding in Menkes disease patients (a 4-patient series, too small to set a population frequency band).

ORPHA:565 SUPPORT Other

"HP:0000015 | Bladder diverticulum | Occasional (29-5%)"

Orphanet's curated HPO frequency annotation classifies bladder diverticulum as Occasional (29-5%) in Menkes disease, supporting the OCCASIONAL band (the small case series alone cannot).

Head and Neck 1

Wormian bones FREQUENT HP:0002645

Show evidence (2 references)

PMID:20180106 SUPPORT Human Clinical

"Skeletal findings in infants with Menkes disease, the most characteristic of which are metaphyseal spurs, long-bone fractures and wormian bones, have been widely reported."

Documents wormian bones as one of the most characteristic skeletal findings in Menkes disease.

ORPHA:565 SUPPORT Other

"HP:0002645 | Wormian bones | Frequent (79-30%)"

Orphanet's curated HPO frequency annotation classifies wormian bones as Frequent (79-30%) in Menkes disease; the band is reconciled from OCCASIONAL up to FREQUENT to match this source.

Integument 3

Pili torti HP:0003777

Frequency band dropped: the evidence is qualitative ("main manifestations") with no frequency data, and pili torti is a best-fit HPO mapping of the quoted "kinky hair". Orphanet (ORPHA:565) carries no HP:0003777 row; the related woolly hair (HP:0002224) and sparse hair (HP:0008070) are classed Very frequent.

Show evidence (1 reference)

PMID:19888294 SUPPORT Human Clinical

"Progressive neurodegeneration and connective tissue disturbances, together with the peculiar 'kinky' hair are the main manifestations."

Supports kinky hair as a hallmark phenotype; pili torti is the best-fit HPO representation.

Cutis laxa HP:0000973

Frequency band dropped: the sole evidence is a single case report, which cannot establish a population frequency. Orphanet (ORPHA:565) carries no HP:0000973 row; the related hyperextensible skin (HP:0000974) and dry skin (HP:0000958) are classed Very frequent.

Show evidence (1 reference)

PMID:22695177 SUPPORT Human Clinical

"His skin was dry and wrinkled with a post-mature quality, and loose and redundant on the back and trunk."

Directly documents the cutis laxa phenotype with loose, redundant, wrinkled skin in a Menkes disease patient.

Fair hair HP:0002286

Frequency band dropped: the cited evidence describes hypopigmented hair as "characteristic" but gives no quantitative or frequency data. Orphanet (ORPHA:565) carries no HP:0002286 row; the sibling term hypopigmentation of hair (HP:0005599) is classed Very frequent.

Show evidence (1 reference)

PMID:29675083 SUPPORT Human Clinical

"These patients can present with failure to thrive, severe psychomotor retardation, seizures and hypopigmented hair, which is characteristic of this condition."

Documents hypopigmented hair as a characteristic clinical feature of Menkes disease.

Musculoskeletal 1

Hypotonia VERY_FREQUENT HP:0001252

Show evidence (2 references)

PMID:22695177 SUPPORT Human Clinical

"Despite this very early intervention with copper, the infant showed hypotonia, developmental delay, and electroencephalographic abnormalities and died of respiratory failure at 5.5 months of age."

Documents hypotonia as a characteristic neurologic manifestation in severe Menkes disease.

ORPHA:565 SUPPORT Other

"HP:0001252 | Hypotonia | Very frequent (99-80%)"

Orphanet's curated HPO frequency annotation classifies hypotonia as Very frequent (99-80%) in Menkes disease; the band is reconciled from FREQUENT up to VERY_FREQUENT to match this source (the prior case-report snippet documented the association but not a frequency).

Nervous System 3

Neurodevelopmental delay HP:0012758

Frequency band dropped: the cited evidence documents onset timing but no quantitative or frequency data. Orphanet (ORPHA:565) carries no HPO frequency row for HP:0012758; the related intellectual disability (HP:0001249) is classed Frequent and developmental regression (HP:0002376) Very frequent.

Show evidence (1 reference)

PMID:25281031 SUPPORT Human Clinical

"Untreated affected individuals suffer failure to thrive and neurodevelopmental delays that usually commence at 6-8 weeks of age."

Documents the characteristic early-onset neurodevelopmental delay of untreated Menkes disease.

Seizures VERY_FREQUENT HP:0001250

Show evidence (2 references)

PMID:32714836 SUPPORT Human Clinical

"At birth, affected Menkes infants appear healthy and typically develop normally for 6 to 10 weeks before seizures, failure to thrive, irreversible brain atrophy, and stalled neurodevelopment ensue."

Identifies seizures as a characteristic early neurologic manifestation.

ORPHA:565 SUPPORT Other

"HP:0001250 | Seizure | Very frequent (99-80%)"

Orphanet's curated HPO frequency annotation classifies seizure as Very frequent (99-80%) in Menkes disease; the band is reconciled from FREQUENT up to VERY_FREQUENT to match this source.

Cerebral atrophy HP:0002059

Frequency band dropped: the cited evidence ("irreversible brain atrophy") documents the association but no quantitative or frequency data. Orphanet (ORPHA:565) carries no HPO frequency row for HP:0002059.

Show evidence (1 reference)

PMID:32714836 SUPPORT Human Clinical

"At birth, affected Menkes infants appear healthy and typically develop normally for 6 to 10 weeks before seizures, failure to thrive, irreversible brain atrophy, and stalled neurodevelopment ensue."

Documents irreversible brain atrophy as a characteristic feature of untreated Menkes disease.

Growth 1

Failure to thrive HP:0001508

Frequency band dropped: the cited evidence documents onset timing but no quantitative or frequency data. Orphanet (ORPHA:565) carries no HPO frequency row for HP:0001508; the related feeding difficulties in infancy (HP:0008872) is classed Very frequent.

Show evidence (1 reference)

PMID:25281031 SUPPORT Human Clinical

"Untreated affected individuals suffer failure to thrive and neurodevelopmental delays that usually commence at 6-8 weeks of age."

Supports failure to thrive as a core early manifestation of untreated Menkes disease.

🧬

Genetic Associations

1

ATP7A pathogenic variants (Loss-of-function)

Gene: ATP7A hgnc:869 relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (4 references)

PMID:18256395 SUPPORT Human Clinical

"Menkes disease is a fatal neurodegenerative disorder of infancy caused by diverse mutations in a copper-transport gene, ATP7A."

Identifies ATP7A as the causal disease gene in Menkes disease.

PMID:20301586 SUPPORT REVIEW SYNTHESIS Human Clinical

"Menkes disease, occipital horn syndrome (OHS), and ATP7A-related distal motor neuropathy (DMN) are disorders caused by pathogenic variants in the ATP7A, the X-linked gene that encodes a copper-transporting ATPase."

The GeneReviews baseline chapter establishes ATP7A as the single gene behind all three subtypes curated in this entry's has_subtypes rows.

DOI:10.1002/jimd.12590 SUPPORT Human Clinical

"Truncating mutations are frequently associated with CMD, in contrast with splice site and intronic mutations which are more prevalent in OHS."

Supports genotype-to-phenotype severity framing across the ATP7A disorder spectrum.

+ 1 more reference

Variants (2)

ATP7A severe loss-of-function variants Pathogenic

Gene: ATP7A hgnc:869

Nonsense, frameshift, splice-site, and copy-number ATP7A variants can severely reduce or abolish copper transport, creating the classic early infantile Menkes pathograph that begins with failed epithelial copper export.

Functional effects

ATP7A copper transport activity loss-of-function

Abrogates or severely reduces ATP7A copper transport activity.

Show evidence (2 references)

PMID:32714836 SUPPORT Human Clinical

"These included eight copy number variants (six large deletions, two large duplications (Fig. 1), four small insertion/deletions causing translational reading frameshifts, as well as three nonsense, three splice junction, and four missense variants."

Supports the spectrum of severe ATP7A variant classes that initiate the Menkes disease mechanism.

DOI:10.1002/jimd.12590 SUPPORT Human Clinical

"Truncating mutations are frequently associated with CMD, in contrast with splice site and intronic mutations which are more prevalent in OHS."

Supports truncating ATP7A variants as enriched in the severe classical Menkes phenotype.

ATP7A residual-function variants Pathogenic

Gene: ATP7A hgnc:869

Some ATP7A variants preserve partial ATPase activity or some correctly spliced transcript, producing residual copper transport that can modify severity and response to early copper treatment.

Functional effects

ATP7A copper transport activity partial loss-of-function

Preserves partial ATP7A copper transport or correctly spliced ATP7A transcript.

Show evidence (2 references)

PMID:18256395 SUPPORT Human Clinical

"Affected newborns who have mutations that do not completely abrogate ATP7A function may be especially responsive to early copper treatment."

Supports residual ATP7A function as a genotype-to-phenotype modifier in Menkes disease.

DOI:10.1002/jimd.12590 SUPPORT Human Clinical

"Truncating mutations are frequently associated with CMD, in contrast with splice site and intronic mutations which are more prevalent in OHS."

Supports splice-site and intronic ATP7A variants as enriched in the residual-function occipital horn syndrome phenotype.

💊

Medical Actions

2

Copper histidinate

Action: copper histidinate therapy Ontology label: Pharmacotherapy NCIT:C15986

Agent: copper histidinate CHEBI:757183

Platform: Small molecule

Early subcutaneous copper histidinate partially bypasses the intestinal copper-transport defect and improves survival and neurodevelopment most effectively when started in the presymptomatic neonatal window. In January 2026 the FDA granted first approval to copper histidinate injection (ZYCUBO) for Menkes disease in pediatric patients.

Mechanism Target:

RESTORES Systemic copper deficiency — Early copper histidinate increases copper availability despite the ATP7A transport defect.

Show evidence (1 reference)

PMID:25281031 SUPPORT Human Clinical

"These can normalize circulating blood levels and may replete brain copper depending on the molecular context, e.g., the severity of ATP7A mutation and potential presence of mosaicism."

Supports copper histidinate as a treatment that restores systemic copper availability and can partially replete brain copper.

RESTORES Brain copper deficiency — Presymptomatic copper histidinate can partially replete brain copper before irreversible neurologic injury.

Show evidence (1 reference)

PMID:25281031 SUPPORT Human Clinical

"These can normalize circulating blood levels and may replete brain copper depending on the molecular context, e.g., the severity of ATP7A mutation and potential presence of mosaicism."

Supports copper histidinate as acting upstream of the neurologic branch when residual molecular context permits brain copper repletion.

Target Phenotypes: Neurodevelopmental delay HP:0012758 Seizure HP:0001250 Failure to thrive HP:0001508

Show evidence (3 references)

PMID:18256395 SUPPORT Human Clinical

"Among 12 newborns with positive screening tests who were treated early with copper, survival at a median follow-up of 4.6 years was 92%, as compared with 13% at a median follow-up of 1.8 years for a historical control group of 15 late-diagnosis and late-treatment patients."

Supports markedly improved survival with early copper treatment relative to late-treated historical controls.

PMID:25281031 SUPPORT Human Clinical

"We conclude that early copper histidine for Menkes disease is safe and efficacious, with treatment outcomes influenced by the timing of intervention, and ATP7A mutation."

Confirms safety and efficacy of early copper histidine treatment and emphasizes the importance of presymptomatic treatment.

PMID:42018271 SUPPORT Other

"In January 2026, copper histidinate received its first approval in the USA by the U.S. Food and Drug Administration for the treatment of Menkes disease in pediatric patients."

Documents the January 2026 FDA first approval of copper histidinate for pediatric Menkes disease, establishing it as an approved therapy rather than compounded-only.

ATP7A gene therapy

Action: gene therapy Ontology label: Gene Therapy NCIT:C15238

Platform: Gene therapy

AAV-mediated ATP7A gene delivery remains investigational but has shown preclinical rescue in Menkes mouse models, particularly when combined with copper histidinate.

Mechanism Target:

RESTORES ATP7A-mediated copper export failure — rAAV9-rsATP7A is intended to supply functional ATP7A and correct the initiating copper-transport defect.

Show evidence (1 reference)

PMID:30090842 SUPPORT Model Organism

"Based on these findings, and the absence of a large animal model, we propose cerebrospinal fluid-directed rAAV9-rsATP7A gene therapy plus subcutaneous copper histidinate as a potential therapeutic approach to cure or ameliorate Menkes disease."

Supports ATP7A gene therapy as targeting the upstream ATP7A transport failure in a Menkes model.

Show evidence (1 reference)

PMID:30090842 SUPPORT Model Organism

"Based on these findings, and the absence of a large animal model, we propose cerebrospinal fluid-directed rAAV9-rsATP7A gene therapy plus subcutaneous copper histidinate as a potential therapeutic approach to cure or ameliorate Menkes disease."

Supports ATP7A gene therapy as an experimental mechanistically targeted treatment emerging from mouse-model rescue studies.

🔬

Biochemical Markers

3

Serum copper (DECREASED)

Show evidence (1 reference)

PMID:22695177 SUPPORT Human Clinical

"Affected individuals manifest low copper and ceruloplasmin levels in plasma or serum, as well as in cerebrospinal fluid."

Confirms low serum copper as a core biochemical feature of Menkes disease.

Serum ceruloplasmin (DECREASED)

Show evidence (1 reference)

PMID:22695177 SUPPORT Human Clinical

"Affected individuals manifest low copper and ceruloplasmin levels in plasma or serum, as well as in cerebrospinal fluid."

Confirms low ceruloplasmin as a diagnostic biochemical marker.

Plasma DOPA:DHPG ratio (INCREASED)

Show evidence (2 references)

PMID:24054147 SUPPORT Human Clinical

"Partial deficiency of dopamine-beta-hydroxylase is a biochemical hallmark of this illness due to the normal role of ATP7A in delivery of copper as an enzymatic cofactor."

Confirms dopamine-beta-hydroxylase deficiency as a sensitive and specific biomarker for Menkes disease.

PMID:18256395 SUPPORT Human Clinical

"Exploiting the deficiency of a copper enzyme, dopamine-beta-hydroxylase, we prospectively evaluated the diagnostic usefulness of plasma neurochemical levels, assessed the clinical effect of early detection, and investigated the molecular bases for treatment outcomes."

Establishes the utility of plasma catecholamine ratios as a diagnostic tool for early detection.

🔬

Diagnosis

2

Plasma catecholamine analysis (POSITIVE)

Distinctive plasma neurochemical pattern with elevated DOPA:DHPG and DOPAC:DHPG ratios enables rapid neonatal diagnosis within hours.

Show evidence (1 reference)

PMID:18256395 SUPPORT Human Clinical

"the neurochemical profiles were shown to have high sensitivity and specificity for detecting disease."

Validates plasma catecholamine analysis as a highly sensitive and specific diagnostic test for Menkes disease.

ATP7A molecular genetic testing (POSITIVE)

Targeted next-generation sequencing of ATP7A detects missense, nonsense, frameshift, splice-site, and copy-number variants with over 95% sensitivity from dried blood spots.

Show evidence (1 reference)

PMID:32714836 SUPPORT Human Clinical

"Our results support proof-of-concept that primary DNA-based NBS would accurately detect Menkes disease, a disorder that fulfills Wilson and Jungner screening criteria and for which biochemical NBS is unavailable."

Supports targeted NGS of ATP7A as a feasible first-tier newborn screening approach for Menkes disease.

📈

Progression

1

Affected infants are often neurologically normal at birth but typically deteriorate after 6 to 10 weeks of age with hypotonia, seizures, failure to thrive, stalled neurodevelopment, and progressive neurodegeneration. Untreated classic disease usually causes death before 3 years of age.

Show evidence (1 reference)

PMID:32714836 SUPPORT Human Clinical

"At birth, affected Menkes infants appear healthy and typically develop normally for 6 to 10 weeks before seizures, failure to thrive, irreversible brain atrophy, and stalled neurodevelopment ensue."

Supports the characteristic early asymptomatic period followed by rapid infantile neurologic decline.

📊

Prevalence

1

Unspecified population

Genome-based analysis of ATP7A predicted a minimum US birth prevalence of approximately 1 in 34,810 live male births for Menkes disease or related ATP7A disorders, with the true prevalence potentially higher if deleterious missense alleles are included.

Show evidence (1 reference)

PMID:32528851 SUPPORT Computational

"Assuming Harvey-Weinberg equilibrium, this frequency of pathogenic alleles predicts 1 in 34,810 live male births with Menkes disease or other ATP7A-related disorders each year in the US."

Supports the minimum genome-based birth prevalence estimate used in the prevalence note.

📊

Related Datasets

1

Whole-Exome Sequencing, Proteome Landscape, and Immune Cell Migration Patterns in a Clinical Context of Menkes Disease DOI:10.3390/genes12050744

Multi-assay Menkes disease resource combining trio whole-exome sequencing, plasma proteomics, and immune-cell migration assays from an ATP7A-affected infant, his parents, and pediatric controls. The plasma proteomics arm is a directly reusable disease-biomarker dataset for systemic consequences of ATP7A dysfunction.

human PROTEOMICS n=7 LC-MS/MS with MaxQuant 1.6.2.6 analysis

blood plasma UBERON:0001969

Conditions: Menkes disease plasma proteome parental carrier/noncarrier comparison pediatric control plasma proteome

PMID:34069220

Show evidence (1 reference)

PMID:34069220 SUPPORT Human Clinical

"Compared with his parents and with child controls, 11 plasma proteins were upregulated and 59 downregulated in the patient."

Supports this publication as a real human Menkes proteomics dataset with disease-versus-control molecular measurements.

🔬

Clinical Trials

1

NCT00811785 PHASE_III COMPLETED

Phase 3 study of daily injected copper histidine for Menkes disease, occipital horn syndrome, and unexplained copper deficiency, evaluating effectiveness, side effects, dosage, and molecular predictors of response.

Target Phenotypes: Neurodevelopmental delay HP:0012758 Seizure HP:0001250 Failure to thrive HP:0001508

Show evidence (1 reference)

clinicaltrials:NCT00811785 SUPPORT Human Clinical

"Patients will receive a prescribed dose of copper histidine, which will be administered daily as an injection."

ClinicalTrials.gov documents the copper histidine intervention used in this Menkes disease treatment study.

🐁

Animal Models

2

Brindled mouse (Atp7a Mo-br)

The brindled allele of the mouse mottled series, the long-standing Menkes model. The study cited here uses it to show that ATP7A is required to load copper onto a secretory cuproenzyme in the trans-Golgi network: aortic and fibroblast SOD3 loses specific activity while cytosolic SOD1 does not, and copper supplementation partially restores it. That rescue is the point of curating this model against an amount-versus-activity node - the enzyme protein is present, and what is missing is its metal cofactor.

Species

Mouse

Genotype

Atp7a<Mo-br>/Y (hemizygous male)

Background

C57BL/6-Atp7a<Mo-br>/J

Alleles

Atp7a<Mo-br>

Genes

ATP7A hgnc:869

Publication

PMID:16371425

Pathograph links

ATP7A-mediated copper export failure recapitulates fidelity: moderate A mutant Atp7a allele reproduces the failure to deliver copper through the secretory pathway, assayed in vascular tissue and cultured fibroblasts.

Limitations: Mo-br is a mouse mottled allele, not a human ATP7A variant, and the copper delivery step is assayed here only for the trans-Golgi/secretory route to SOD3. The study is a vascular-biology investigation rather than a Menkes natural-history study.

Readouts

SOD3 specific activity in aorta and cultured fibroblasts

Direction: DECREASED

Interpretation: A specific-activity measurement that falls without the enzyme protein being lost, and is partially restored by adding copper - the cofactor-deficiency pattern in which activity and amount dissociate. Cytosolic SOD1 is unaffected, which localizes the lesion to the secretory route ATP7A serves.

Show evidence (1 reference)

PMID:16371425 SUPPORT Model Organism

"Aortas and cultured fibroblasts from MNK mutant (MNK(mut)) mice showed a marked decrease in specific activity of SOD3, but not SOD1 (cytosolic form), which was partially restored by copper addition."

Reports the cuproenzyme specific-activity deficit and its rescue by copper, which together establish the defect as cofactor loading rather than enzyme loss.

Show evidence (1 reference)

PMID:16371425 SUPPORT Model Organism

"In conclusion, vascular MNK plays an essential role in full activity of SOD3 through transporting copper to SOD3 in the TGN, thereby regulating O2*- levels in the vasculature."

States the transporter-to-cuproenzyme dependency that makes this mutant informative for the copper export node.

Cuproenzyme deficiency and neurodevelopmental injury partially recapitulates fidelity: low Demonstrates cuproenzyme inactivation downstream of ATP7A loss, with the expected oxidative consequence when the cuproenzyme is an antioxidant.

Limitations: The cuproenzyme measured is vascular SOD3, not the neuronal cuproenzymes (cytochrome c oxidase, dopamine beta-hydroxylase, peptidylglycine alpha-amidating monooxygenase) through which Menkes disease produces its neurodevelopmental phenotype. No neurologic or developmental outcome is assessed in this study, so the model supports the cuproenzyme half of this node and says nothing about the injury half.

Readouts

Vascular superoxide anion level

Direction: INCREASED

Interpretation: The oxidative consequence of losing an extracellular cuproenzyme's activity in aortic tissue.

Show evidence (1 reference)

PMID:16371425 SUPPORT Model Organism

"Aortas of MNK(mut) mice revealed a decrease in activity of SOD3, but not SOD1, in association with a robust increase in O2*- levels."

Links the cuproenzyme activity loss to a measured rise in superoxide.

Show evidence (1 reference)

PMID:16371425 SUPPORT Model Organism

"Here we show that MNK was highly expressed in the various vascular tissues and cells."

Establishes that the transporter is expressed where the cuproenzyme deficit was measured, which is what makes this mutant informative for the cuproenzyme node - noting the measurement is vascular, not neuronal.

Viable brindled mouse (Atp7a Mo-vbr)

A viable mottled allele assessed by 31P magnetic resonance spectroscopy and enzymology as a model of mitochondrial impairment. Two respiratory-chain activities are reduced in a tissue-specific pattern - succinate-cytochrome c reductase in muscle and the copper-dependent cytochrome oxidase in brain - and phosphocreatine recovery after exercise is slowed. Only cytochrome oxidase (complex IV) is a cuproenzyme; succinate-cytochrome c reductase spans complexes II and III, which use flavin, iron-sulfur clusters and hemes, so the muscle deficit is not itself evidence of cuproenzyme failure.

Species

Mouse

Genotype

Atp7a<Mo-vbr>/Y (hemizygous male)

Alleles

Atp7a<Mo-vbr>

Genes

ATP7A hgnc:869

Publication

PMID:9342151

Pathograph links

Cuproenzyme deficiency and neurodevelopmental injury partially recapitulates fidelity: moderate Reduced cytochrome oxidase activity in brain is the cuproenzyme deficit that this node names, measured directly in the tissue where Menkes disease causes neurodegeneration.

Limitations: The study measures enzyme activities and energetics, not neurodevelopmental outcome, so it substantiates the cuproenzyme arm rather than the injury arm. The deficits are tissue-restricted - cytochrome oxidase is reduced in brain but not muscle - so a single-tissue assay does not generalize across organs. Mo-vbr is a mouse allele, not a human ATP7A variant.

Readouts

Cytochrome oxidase activity in brain

Direction: DECREASED

Interpretation: Direct catalytic-activity measurement of a copper-dependent respiratory-chain enzyme in the affected tissue.

Show evidence (1 reference)

PMID:9342151 SUPPORT Model Organism

"The maximal activity of succinate-cytochrome c reductase was significantly reduced in mo(vbr) muscle compared to controls, whereas cytochrome oxidase activity was only reduced in mo(vbr) brain."

Reports both respiratory-chain activity deficits and their tissue specificity.

Show evidence (1 reference)

PMID:9342151 SUPPORT Model Organism

"We conclude that mo(vbr) brain and muscle tissue have biochemical abnormalities consistent with mitochondrial impairment."

The authors' summary of the enzymatic and energetic deficits that make this mutant informative for the cuproenzyme node.

{ }

Source YAML

click to show

name: Menkes Disease
creation_date: '2026-03-15T23:36:00Z'
category: Genetic
synonyms:
- Menkes disease
- Menkes kinky hair syndrome
- kinky hair disease
- ATP7A-related copper transport disorder
- Trichopoliodystrophy
- Steely disease
description: >-
  Menkes disease is an X-linked disorder of copper transport caused by
  pathogenic ATP7A variants. Loss of ATP7A function blocks copper export from
  enterocytes and other polarized epithelia, causing systemic copper deficiency
  with paradoxical copper trapping in selected tissues and poor copper delivery
  to the developing brain. Downstream deficiency of copper-dependent enzymes,
  including dopamine-beta-hydroxylase, cytochrome c oxidase, lysyl oxidase, and
  tyrosinase, drives progressive neurodevelopmental impairment, seizures,
  hypotonia, failure to thrive, connective-tissue fragility, and the
  characteristic kinky hair phenotype.
disease_term:
  preferred_term: Menkes disease
  term:
    id: MONDO:0010651
    label: Menkes disease
parents:
- Copper metabolism disorder
- Neurodevelopmental disease
- Connective tissue disorder
inheritance:
- name: X-linked recessive inheritance
  description: >-
    Menkes disease is inherited as an X-linked recessive disorder caused by
    ATP7A variants, with classic disease occurring predominantly in hemizygous
    males.
  evidence:
  - reference: PMID:19888294
    reference_title: "Menkes disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MD is inherited as an X-linked recessive trait, and as expected the vast majority of patients are males."
    explanation: Supports the canonical X-linked recessive inheritance pattern of Menkes disease.
prevalence:
- notes: >-
    Genome-based analysis of ATP7A predicted a minimum US birth prevalence of
    approximately 1 in 34,810 live male births for Menkes disease or related
    ATP7A disorders, with the true prevalence potentially higher if deleterious
    missense alleles are included.
  evidence:
  - reference: PMID:32528851
    reference_title: "Estimated birth prevalence of Menkes disease and ATP7A-related disorders based on the Genome Aggregation Database (gnomAD)."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "Assuming Harvey-Weinberg equilibrium, this frequency of pathogenic alleles predicts 1 in 34,810 live male births with Menkes disease or other ATP7A-related disorders each year in the US."
    explanation: Supports the minimum genome-based birth prevalence estimate used in the prevalence note.
progression:
- notes: >-
    Affected infants are often neurologically normal at birth but typically
    deteriorate after 6 to 10 weeks of age with hypotonia, seizures, failure to
    thrive, stalled neurodevelopment, and progressive neurodegeneration.
    Untreated classic disease usually causes death before 3 years of age.
  evidence:
  - reference: PMID:32714836
    reference_title: "Targeted next generation sequencing for newborn screening of Menkes disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At birth, affected Menkes infants appear healthy and typically develop normally for 6 to 10 weeks before seizures, failure to thrive, irreversible brain atrophy, and stalled neurodevelopment ensue."
    explanation: Supports the characteristic early asymptomatic period followed by rapid infantile neurologic decline.
genetic:
- name: ATP7A pathogenic variants
  gene_term:
    preferred_term: ATP7A
    term:
      id: hgnc:869
      label: ATP7A
  association: Loss-of-function
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  presence: Positive
  notes: >-
    ATP7A encodes a copper-transporting P-type ATPase required for copper export
    across polarized epithelia and copper delivery to secretory-pathway
    cuproenzymes. Disease-causing variants include missense, nonsense,
    frameshift, splice-site, and copy-number defects, with more severe
    phenotypes generally associated with variants that abolish residual copper
    transport.
  evidence:
  - reference: PMID:18256395
    reference_title: "Neonatal diagnosis and treatment of Menkes disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Menkes disease is a fatal neurodegenerative disorder of infancy caused by diverse mutations in a copper-transport gene, ATP7A."
    explanation: Identifies ATP7A as the causal disease gene in Menkes disease.
  - reference: PMID:20301586
    reference_title: ATP7A-Related Copper Transport Disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Menkes disease, occipital horn syndrome (OHS), and ATP7A-related distal motor neuropathy (DMN) are disorders caused by pathogenic variants in the ATP7A, the X-linked gene that encodes a copper-transporting ATPase."
    explanation: >-
      The GeneReviews baseline chapter establishes ATP7A as the single gene behind
      all three subtypes curated in this entry's has_subtypes rows.
  - reference: DOI:10.1002/jimd.12590
    reference_title: "<scp><i>ATP7A</i></scp>‐related copper transport disorders: A systematic review and definition of the clinical subtypes"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Truncating mutations are frequently associated with CMD, in contrast with splice site and intronic mutations which are more prevalent in OHS."
    explanation: Supports genotype-to-phenotype severity framing across the ATP7A disorder spectrum.
  - reference: CGGV:assertion_9bc50734-316b-47db-ba10-61f3fde46cca-2018-02-07T110000.000Z
    reference_title: "ATP7A / Menkes disease (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ATP7A | HGNC:869 | Menkes disease | MONDO:0010651 | XL | Definitive"
    explanation: ClinGen classifies the ATP7A-Menkes disease gene-disease relationship as definitive with X-linked inheritance.
  variants:
  - name: ATP7A severe loss-of-function variants
    description: >-
      Nonsense, frameshift, splice-site, and copy-number ATP7A variants can
      severely reduce or abolish copper transport, creating the classic early
      infantile Menkes pathograph that begins with failed epithelial copper
      export.
    gene:
      preferred_term: ATP7A
      term:
        id: hgnc:869
        label: ATP7A
    clinical_significance: PATHOGENIC
    functional_effects:
    - function: ATP7A copper transport activity
      description: Abrogates or severely reduces ATP7A copper transport activity.
      type: loss-of-function
    evidence:
    - reference: PMID:32714836
      reference_title: "Targeted next generation sequencing for newborn screening of Menkes disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "These included eight copy number variants (six large deletions, two large duplications (Fig. 1), four small insertion/deletions causing translational reading frameshifts, as well as three nonsense, three splice junction, and four missense variants."
      explanation: Supports the spectrum of severe ATP7A variant classes that initiate the Menkes disease mechanism.
    - reference: DOI:10.1002/jimd.12590
      reference_title: "<scp><i>ATP7A</i></scp>‐related copper transport disorders: A systematic review and definition of the clinical subtypes"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Truncating mutations are frequently associated with CMD, in contrast with splice site and intronic mutations which are more prevalent in OHS."
      explanation: Supports truncating ATP7A variants as enriched in the severe classical Menkes phenotype.
  - name: ATP7A residual-function variants
    description: >-
      Some ATP7A variants preserve partial ATPase activity or some correctly
      spliced transcript, producing residual copper transport that can modify
      severity and response to early copper treatment.
    gene:
      preferred_term: ATP7A
      term:
        id: hgnc:869
        label: ATP7A
    clinical_significance: PATHOGENIC
    functional_effects:
    - function: ATP7A copper transport activity
      description: Preserves partial ATP7A copper transport or correctly spliced ATP7A transcript.
      type: partial loss-of-function
    evidence:
    - reference: PMID:18256395
      reference_title: "Neonatal diagnosis and treatment of Menkes disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Affected newborns who have mutations that do not completely abrogate ATP7A function may be especially responsive to early copper treatment."
      explanation: Supports residual ATP7A function as a genotype-to-phenotype modifier in Menkes disease.
    - reference: DOI:10.1002/jimd.12590
      reference_title: "<scp><i>ATP7A</i></scp>‐related copper transport disorders: A systematic review and definition of the clinical subtypes"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Truncating mutations are frequently associated with CMD, in contrast with splice site and intronic mutations which are more prevalent in OHS."
      explanation: Supports splice-site and intronic ATP7A variants as enriched in the residual-function occipital horn syndrome phenotype.
pathophysiology:
- name: ATP7A-mediated copper export failure
  biological_scale: MOLECULAR
  description: >-
    ATP7A dysfunction impairs copper movement from the cytosol into the
    secretory pathway and prevents directional copper export across polarized
    epithelial barriers. The result is low circulating copper availability with
    copper retention in intestinal and renal epithelia and inadequate delivery
    to peripheral tissues and the brain.
  genes:
  - preferred_term: ATP7A
    term:
      id: hgnc:869
      label: ATP7A
  molecular_functions:
  - preferred_term: P-type monovalent copper transporter activity
    term:
      id: GO:0140581
      label: P-type monovalent copper transporter activity
    modifier: DECREASED
  cell_types:
  - preferred_term: enterocyte
    term:
      id: CL:0000584
      label: enterocyte
  - preferred_term: epithelial cell of proximal tubule
    term:
      id: CL:0002306
      label: epithelial cell of proximal tubule
  biological_processes:
  - preferred_term: copper ion transport
    term:
      id: GO:0006825
      label: copper ion transport
    modifier: DECREASED
  cellular_components:
  - preferred_term: Golgi apparatus
    term:
      id: GO:0005794
      label: Golgi apparatus
  locations:
  - preferred_term: small intestine
    term:
      id: UBERON:0002108
      label: small intestine
  - preferred_term: kidney
    term:
      id: UBERON:0002113
      label: kidney
  evidence:
  - reference: PMID:19888294
    reference_title: "Menkes disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ATP7A is an energy dependent transmembrane protein, which is involved in the delivery of copper to the secreted copper enzymes and in the export of surplus copper from cells."
    explanation: Supports ATP7A as the central mediator of intracellular copper delivery and cellular copper efflux.
  - reference: PMID:27226607
    reference_title: "The Activity of Menkes Disease Protein ATP7A Is Essential for Redox Balance in Mitochondria."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In cells, ATP7A inactivation disrupts copper transport from the cytosol into the secretory pathway."
    explanation: Demonstrates that ATP7A loss directly disrupts secretory-pathway copper trafficking.
  downstream:
  - target: Systemic copper deficiency
    description: Failed epithelial copper export lowers circulating copper and ceruloplasmin availability.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24054147
      reference_title: "Catecholamine metabolites affected by the copper-dependent enzyme dopamine-beta-hydroxylase provide sensitive biomarkers for early diagnosis of menkes disease and viral-mediated ATP7A gene therapy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Both conditions are linked to a biochemical phenotype (low copper levels in the blood and a copper deficiency in the brain) that denotes abnormal copper metabolism."
      explanation: Supports low blood copper as a direct downstream consequence of ATP7A-mediated copper transport failure in Menkes disease.
  - target: Brain copper deficiency
    description: Inadequate copper transfer across brain barriers limits neuronal copper delivery during development.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24054147
      reference_title: "Catecholamine metabolites affected by the copper-dependent enzyme dopamine-beta-hydroxylase provide sensitive biomarkers for early diagnosis of menkes disease and viral-mediated ATP7A gene therapy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Passage of copper across the blood-cerebrospinal fluid (CSF) barrier and the blood-brain barrier (BBB) is likely mediated by ATP7A."
      explanation: Supports ATP7A-dependent copper transfer into the CNS and therefore brain copper deficiency when ATP7A function is lost.
  - target: Mitochondrial redox imbalance from copper accumulation
    description: ATP7A inactivation can also cause paradoxical intracellular copper accumulation and mitochondrial redox injury.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:27226607
      reference_title: "The Activity of Menkes Disease Protein ATP7A Is Essential for Redox Balance in Mitochondria."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "In cells, ATP7A inactivation disrupts copper transport from the cytosol into the secretory pathway."
      explanation: Supports ATP7A inactivation as the upstream event leading to abnormal intracellular copper handling and mitochondrial redox stress.
- name: Systemic copper deficiency
  biological_scale: ORGANISM
  description: >-
    Failed ATP7A-dependent epithelial copper export causes low circulating
    copper and ceruloplasmin. Systemic copper deficiency limits copper delivery
    to secretory-pathway cuproenzymes in peripheral tissues.
  biological_processes:
  - preferred_term: copper ion homeostasis
    term:
      id: GO:0055070
      label: copper ion homeostasis
    modifier: ABNORMAL
  locations:
  - preferred_term: blood plasma
    term:
      id: UBERON:0001969
      label: blood plasma
  evidence:
  - reference: PMID:22695177
    reference_title: "In utero copper treatment for Menkes disease associated with a severe ATP7A mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Affected individuals manifest low copper and ceruloplasmin levels in plasma or serum, as well as in cerebrospinal fluid."
    explanation: Supports systemic copper and ceruloplasmin deficiency as a core biochemical state downstream of ATP7A dysfunction.
  downstream:
  - target: Serum copper
    description: Reduced systemic copper availability is measured clinically as low serum copper.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:22695177
      reference_title: "In utero copper treatment for Menkes disease associated with a severe ATP7A mutation."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Affected individuals manifest low copper and ceruloplasmin levels in plasma or serum, as well as in cerebrospinal fluid."
      explanation: Directly supports low serum copper as the biochemical readout of systemic copper deficiency.
  - target: Serum ceruloplasmin
    description: Inadequate copper availability reduces circulating ceruloplasmin.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:22695177
      reference_title: "In utero copper treatment for Menkes disease associated with a severe ATP7A mutation."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Affected individuals manifest low copper and ceruloplasmin levels in plasma or serum, as well as in cerebrospinal fluid."
      explanation: Directly supports low ceruloplasmin as a biochemical readout of systemic copper deficiency.
  - target: Lysyl oxidase deficiency and connective tissue fragility
    description: Peripheral copper deficiency reduces activity of the copper-dependent connective-tissue enzyme lysyl oxidase.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:32293788
      reference_title: "Neck masses due to internal jugular vein phlebectasia: Frequency in Menkes disease and literature review of 85 pediatric subjects."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "This feature and other connective tissue abnormalities appear to be consequences of deficient activity of lysyl oxidase, a copper-dependent enzyme."
      explanation: Supports lysyl oxidase deficiency as a copper-dependent peripheral mechanism downstream of systemic copper deficiency.
  - target: Hair-shaft keratinization and pigmentation enzyme dysfunction
    description: Inadequate copper delivery to hair-shaft and pigment enzymes causes the characteristic kinky and hypopigmented hair phenotype.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - impaired copper-dependent hair-shaft enzyme activity
    - impaired melanin biosynthesis
    evidence:
    - reference: PMID:19888294
      reference_title: "Menkes disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Progressive neurodegeneration and connective tissue disturbances, together with the peculiar 'kinky' hair are the main manifestations."
      explanation: Supports the hair phenotype as a downstream manifestation of the systemic copper-transport disorder.
- name: Brain copper deficiency
  biological_scale: TISSUE
  description: >-
    ATP7A-dependent copper transfer across brain barriers is inadequate,
    limiting copper availability to developing neurons and CNS cuproenzymes
    during the brief presymptomatic neonatal window.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: copper ion transport
    term:
      id: GO:0006825
      label: copper ion transport
    modifier: DECREASED
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  evidence:
  - reference: PMID:24054147
    reference_title: "Catecholamine metabolites affected by the copper-dependent enzyme dopamine-beta-hydroxylase provide sensitive biomarkers for early diagnosis of menkes disease and viral-mediated ATP7A gene therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Both conditions are linked to a biochemical phenotype (low copper levels in the blood and a copper deficiency in the brain) that denotes abnormal copper metabolism."
    explanation: Supports brain copper deficiency as a core biochemical mechanism in Menkes disease.
  downstream:
  - target: Cuproenzyme deficiency and neurodevelopmental injury
    description: Brain copper deficiency impairs copper-dependent enzymes needed for catecholamine synthesis and mitochondrial energy metabolism.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:18256395
      reference_title: "Neonatal diagnosis and treatment of Menkes disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Exploiting the deficiency of a copper enzyme, dopamine-beta-hydroxylase, we prospectively evaluated the diagnostic usefulness of plasma neurochemical levels, assessed the clinical effect of early detection, and investigated the molecular bases for treatment outcomes."
      explanation: Supports cuproenzyme deficiency as a direct biochemical consequence of inadequate brain copper delivery.
- name: Cuproenzyme deficiency and neurodevelopmental injury
  biological_scale: CELLULAR
  description: >-
    Brain copper deficiency compromises copper-dependent enzymes, especially
    dopamine-beta-hydroxylase and cytochrome c oxidase. This causes abnormal
    catecholamine biosynthesis, impaired oxidative phosphorylation, and
    progressive neurodevelopmental injury with seizures, hypotonia, and brain
    atrophy.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  molecular_functions:
  - preferred_term: dopamine beta-monooxygenase (dopamine-beta-hydroxylase) activity
    term:
      id: GO:0004500
      label: dopamine beta-monooxygenase activity
    modifier: DECREASED
  - preferred_term: cytochrome-c oxidase activity
    term:
      id: GO:0004129
      label: cytochrome-c oxidase activity
    modifier: DECREASED
  biological_processes:
  - preferred_term: catecholamine biosynthetic process
    term:
      id: GO:0042423
      label: catecholamine biosynthetic process
    modifier: DECREASED
  - preferred_term: oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
    modifier: DECREASED
  cellular_components:
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  evidence:
  - reference: PMID:18256395
    reference_title: "Neonatal diagnosis and treatment of Menkes disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Exploiting the deficiency of a copper enzyme, dopamine-beta-hydroxylase, we prospectively evaluated the diagnostic usefulness of plasma neurochemical levels, assessed the clinical effect of early detection, and investigated the molecular bases for treatment outcomes."
    explanation: Supports dopamine-beta-hydroxylase deficiency as a measurable biochemical consequence of Menkes disease.
  - reference: PMID:32381719
    reference_title: "Elesclomol alleviates Menkes pathology and mortality by escorting Cu to cuproenzymes in mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Here we report that the small molecule elesclomol escorted copper to the mitochondria and increased cytochrome c oxidase levels in the brain."
    explanation: >-
      The study's own in-vivo result: restoring mitochondrial copper raises
      cytochrome c oxidase in Menkes-model brain, grounding the reduced
      cytochrome-c-oxidase-activity and oxidative-phosphorylation annotations on
      this node from the intervention rather than from background.
  - reference: PMID:32714836
    reference_title: "Targeted next generation sequencing for newborn screening of Menkes disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At birth, affected Menkes infants appear healthy and typically develop normally for 6 to 10 weeks before seizures, failure to thrive, irreversible brain atrophy, and stalled neurodevelopment ensue."
    explanation: Connects early copper-handling defects to the characteristic neurologic decline and brain atrophy seen in infants.
  downstream:
  - target: Seizures
    description: Neuronal copper deficiency lowers seizure threshold and contributes to epileptic manifestations.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:32714836
      reference_title: "Targeted next generation sequencing for newborn screening of Menkes disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "At birth, affected Menkes infants appear healthy and typically develop normally for 6 to 10 weeks before seizures, failure to thrive, irreversible brain atrophy, and stalled neurodevelopment ensue."
      explanation: Supports seizures as a downstream neurologic manifestation of early brain copper deficiency in Menkes disease.
  - target: Neurodevelopmental delay
    description: Impaired energy metabolism and catecholamine synthesis disrupt normal brain growth and development.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:25281031
      reference_title: "Neurodevelopment and brain growth in classic Menkes disease is influenced by age and symptomatology at initiation of copper treatment."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Untreated affected individuals suffer failure to thrive and neurodevelopmental delays that usually commence at 6-8 weeks of age."
      explanation: Supports neurodevelopmental delay as a downstream consequence of ATP7A-related copper-dependent neuronal dysfunction.
  - target: Cerebral atrophy
    description: Impaired copper-dependent neuronal metabolism contributes to irreversible brain atrophy.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:32714836
      reference_title: "Targeted next generation sequencing for newborn screening of Menkes disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "At birth, affected Menkes infants appear healthy and typically develop normally for 6 to 10 weeks before seizures, failure to thrive, irreversible brain atrophy, and stalled neurodevelopment ensue."
      explanation: Directly links the neurodevelopmental disease course to irreversible brain atrophy.
  - target: Hypotonia
    description: Neurologic injury from cuproenzyme deficiency manifests clinically as hypotonia.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:22695177
      reference_title: "In utero copper treatment for Menkes disease associated with a severe ATP7A mutation."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Despite this very early intervention with copper, the infant showed hypotonia, developmental delay, and electroencephalographic abnormalities and died of respiratory failure at 5.5 months of age."
      explanation: Supports hypotonia as a downstream neurologic manifestation in severe Menkes disease.
  - target: Failure to thrive
    description: Early neurologic dysfunction and systemic copper deficiency contribute to poor growth.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:25281031
      reference_title: "Neurodevelopment and brain growth in classic Menkes disease is influenced by age and symptomatology at initiation of copper treatment."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Untreated affected individuals suffer failure to thrive and neurodevelopmental delays that usually commence at 6-8 weeks of age."
      explanation: Supports failure to thrive as a downstream clinical outcome of untreated copper-dependent neurodevelopmental injury.
  - target: Plasma DOPA:DHPG ratio
    description: Dopamine-beta-hydroxylase deficiency increases diagnostic catecholamine metabolite ratios.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24054147
      reference_title: "Catecholamine metabolites affected by the copper-dependent enzyme dopamine-beta-hydroxylase provide sensitive biomarkers for early diagnosis of menkes disease and viral-mediated ATP7A gene therapy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Partial deficiency of dopamine-beta-hydroxylase is a biochemical hallmark of this illness due to the normal role of ATP7A in delivery of copper as an enzymatic cofactor."
      explanation: Directly links cuproenzyme deficiency to the elevated catecholamine metabolite ratio used diagnostically.
- name: Mitochondrial redox imbalance from copper accumulation
  biological_scale: CELLULAR
  description: >-
    In cells lacking functional ATP7A, copper accumulates in mitochondria and
    disrupts glutathione-based redox buffering. This renders cells highly
    sensitive to oxidative stress and contributes to tissue injury, particularly
    in renal epithelia where copper paradoxically accumulates.
  cell_types:
  - preferred_term: epithelial cell of proximal tubule
    term:
      id: CL:0002306
      label: epithelial cell of proximal tubule
  biological_processes:
  - preferred_term: cellular response to oxidative stress
    term:
      id: GO:0034599
      label: cellular response to oxidative stress
    modifier: INCREASED
  cellular_components:
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
  locations:
  - preferred_term: kidney
    term:
      id: UBERON:0002113
      label: kidney
  evidence:
  - reference: PMID:27226607
    reference_title: "The Activity of Menkes Disease Protein ATP7A Is Essential for Redox Balance in Mitochondria."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Redox misbalance does not significantly affect mitochondrion morphology or the activity of respiratory complex IV but markedly increases cell sensitivity to even mild glutathione depletion, resulting in loss of cell viability."
    explanation: Demonstrates that ATP7A loss causes mitochondrial redox imbalance and increased sensitivity to glutathione depletion.
  - reference: PMID:27226607
    reference_title: "The Activity of Menkes Disease Protein ATP7A Is Essential for Redox Balance in Mitochondria."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Mitochondrial redox misbalance could significantly contribute to pathologies associated with ATP7A inactivation in tissues with paradoxical accumulation of copper (i.e. renal epithelia)."
    explanation: Identifies renal epithelia as a key tissue where mitochondrial redox imbalance contributes to Menkes pathology.
- name: Lysyl oxidase deficiency and connective tissue fragility
  biological_scale: TISSUE
  description: >-
    Copper deficiency reduces lysyl oxidase activity, weakening collagen and
    elastin cross-linking in connective tissues and vessel walls. This produces
    tissue laxity, vascular tortuosity and phlebectasia, hernias, and skeletal
    fragility.
  molecular_functions:
  - preferred_term: lysyl oxidase (protein-lysine 6-oxidase) activity
    term:
      id: GO:0004720
      label: protein-lysine 6-oxidase activity
    modifier: DECREASED
  biological_processes:
  - preferred_term: extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
    modifier: DECREASED
  locations:
  - preferred_term: skin
    term:
      id: UBERON:0002097
      label: skin of body
  - preferred_term: blood vessel
    term:
      id: UBERON:0001981
      label: blood vessel
  evidence:
  - reference: PMID:32293788
    reference_title: "Neck masses due to internal jugular vein phlebectasia: Frequency in Menkes disease and literature review of 85 pediatric subjects."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This feature and other connective tissue abnormalities appear to be consequences of deficient activity of lysyl oxidase, a copper-dependent enzyme."
    explanation: Directly links connective-tissue manifestations in Menkes disease to lysyl oxidase deficiency.
  downstream:
  - target: Vascular tortuosity and phlebectasia
    description: Defective extracellular-matrix cross-linking weakens vessel walls and alters vascular architecture.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:32293788
      reference_title: "Neck masses due to internal jugular vein phlebectasia: Frequency in Menkes disease and literature review of 85 pediatric subjects."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "We previously identified internal jugular vein phlebectasia (IJP) in four Menkes disease subjects. This feature and other connective tissue abnormalities appear to be consequences of deficient activity of lysyl oxidase, a copper-dependent enzyme."
      explanation: Supports vascular phlebectasia as a connective-tissue downstream effect of lysyl oxidase deficiency in Menkes disease.
  - target: Connective tissue laxity
    description: Weak collagen and elastin cross-linking contributes to hernias, skin laxity, and skeletal complications.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:32293788
      reference_title: "Neck masses due to internal jugular vein phlebectasia: Frequency in Menkes disease and literature review of 85 pediatric subjects."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "This feature and other connective tissue abnormalities appear to be consequences of deficient activity of lysyl oxidase, a copper-dependent enzyme."
      explanation: Supports generalized connective-tissue fragility and laxity as downstream consequences of reduced lysyl oxidase activity.
- name: Vascular tortuosity and phlebectasia
  biological_scale: TISSUE
  description: >-
    Weak elastin and collagen cross-linking in vessel walls leads to tortuous
    intracranial arteries and benign internal jugular vein phlebectasia.
  biological_processes:
  - preferred_term: extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
    modifier: DECREASED
  locations:
  - preferred_term: blood vessel
    term:
      id: UBERON:0001981
      label: blood vessel
  evidence:
  - reference: PMID:32293788
    reference_title: "Neck masses due to internal jugular vein phlebectasia: Frequency in Menkes disease and literature review of 85 pediatric subjects."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We previously identified internal jugular vein phlebectasia (IJP) in four Menkes disease subjects. This feature and other connective tissue abnormalities appear to be consequences of deficient activity of lysyl oxidase, a copper-dependent enzyme."
    explanation: Supports vascular phlebectasia as a downstream vascular-wall manifestation of lysyl oxidase deficiency.
  downstream:
  - target: Arterial tortuosity
    description: Vessel-wall matrix weakness produces tortuous intracranial arteries.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:31198482
      reference_title: "Imaging findings of Menkes disease, a radiographic mimic of abusive trauma."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The classic radiographic findings seen in Menke's disease have been documented and include wormian bones, diaphyseal and metaphyseal bone fractures, subdural hematomas, and tortuous intracranial arteries"
      explanation: Documents arterial tortuosity as a vascular phenotype downstream of connective-tissue vessel-wall fragility.
  - target: Internal jugular vein phlebectasia
    description: Venous wall weakness produces fusiform internal jugular vein dilatation.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:32293788
      reference_title: "Neck masses due to internal jugular vein phlebectasia: Frequency in Menkes disease and literature review of 85 pediatric subjects."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Our prospective results suggest that IJP occurs in approximately 14% (9/66) of Menkes disease patients and appears to be clinically benign with no specific medical or surgical actionability."
      explanation: Directly supports internal jugular vein phlebectasia as a Menkes vascular phenotype.
- name: Connective tissue laxity
  biological_scale: TISSUE
  description: >-
    Reduced extracellular-matrix cross-linking weakens skin, bladder wall,
    cranial sutures, bones, and bridging vessels, producing the connective
    tissue phenotype branch of Menkes disease.
  biological_processes:
  - preferred_term: extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
    modifier: DECREASED
  locations:
  - preferred_term: skin
    term:
      id: UBERON:0002097
      label: skin of body
  evidence:
  - reference: PMID:32293788
    reference_title: "Neck masses due to internal jugular vein phlebectasia: Frequency in Menkes disease and literature review of 85 pediatric subjects."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This feature and other connective tissue abnormalities appear to be consequences of deficient activity of lysyl oxidase, a copper-dependent enzyme."
    explanation: Supports generalized connective-tissue laxity as a downstream manifestation of lysyl oxidase deficiency.
  downstream:
  - target: Cutis laxa
    description: Defective collagen and elastin cross-linking causes loose, redundant, wrinkled skin.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:22695177
      reference_title: "In utero copper treatment for Menkes disease associated with a severe ATP7A mutation."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "His skin was dry and wrinkled with a post-mature quality, and loose and redundant on the back and trunk."
      explanation: Directly supports cutis laxa as a connective-tissue manifestation.
  - target: Bladder diverticulum
    description: Weak bladder-wall connective tissue predisposes to diverticula.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:406641
      reference_title: "Bladder diverticula and Menkes' syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Multiple unusual diverticula of the bladder were observed in 3 of 4 children with Menkes' syndrome."
      explanation: Supports bladder diverticula as a downstream connective-tissue phenotype.
  - target: Wormian bones
    description: Skeletal connective-tissue and mineralization abnormalities include wormian bones.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20180106
      reference_title: "Long-term skeletal findings in Menkes disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Skeletal findings in infants with Menkes disease, the most characteristic of which are metaphyseal spurs, long-bone fractures and wormian bones, have been widely reported."
      explanation: Supports wormian bones as a skeletal outcome of the connective-tissue phenotype branch.
  - target: Subdural hemorrhage
    description: Fragile connective tissue and vessels predispose to subdural hemorrhage.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - bridging vein fragility
    evidence:
    - reference: PMID:12483361
      reference_title: "Massive subdural haematomas in Menkes disease mimicking shaken baby syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "We present a case of Menkes disease complicated by progressive macrocephaly following the development of massive subdural haematomas."
      explanation: Supports subdural hemorrhage as a downstream vascular-connective tissue complication.
- name: Hair-shaft keratinization and pigmentation enzyme dysfunction
  biological_scale: CELLULAR
  description: >-
    Copper-dependent hair and pigment biology is disrupted, producing brittle
    twisted hair shafts and hair hypopigmentation. Reduced activity of the
    copper-dependent enzyme tyrosinase impairs melanin biosynthesis, while
    defective disulfide cross-linking weakens the keratinized hair shaft.
  molecular_functions:
  - preferred_term: tyrosinase activity
    term:
      id: GO:0004503
      label: tyrosinase activity
    modifier: DECREASED
  biological_processes:
  - preferred_term: melanin biosynthetic process
    term:
      id: GO:0042438
      label: melanin biosynthetic process
    modifier: DECREASED
  locations:
  - preferred_term: hair follicle
    term:
      id: UBERON:0002073
      label: hair follicle
  evidence:
  - reference: PMID:19888294
    reference_title: "Menkes disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Progressive neurodegeneration and connective tissue disturbances, together with the peculiar 'kinky' hair are the main manifestations."
    explanation: Supports kinky hair as a core Menkes manifestation downstream of copper-transport disruption.
  - reference: PMID:18650808
    reference_title: "Cell-specific ATP7A transport sustains copper-dependent tyrosinase activity in melanosomes."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Copper is supplied to melanosomes by ATP7A"
    explanation: >-
      Establishes that ATP7A supplies the copper that activates the pigment-cell
      cuproenzyme tyrosinase in melanosomes, grounding the reduced
      tyrosinase-activity and melanin-biosynthesis annotations for the
      hypopigmentation branch.
  downstream:
  - target: Pili torti
    description: Hair-shaft structural disruption produces twisted, brittle pili torti.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:19888294
      reference_title: "Menkes disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Progressive neurodegeneration and connective tissue disturbances, together with the peculiar 'kinky' hair are the main manifestations."
      explanation: Supports kinky hair as the clinical correlate represented by the pili torti HPO term.
  - target: Fair hair
    description: Impaired pigment enzyme activity produces hypopigmented fair hair.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:29675083
      reference_title: "Neuroimaging in Menkes Disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "These patients can present with failure to thrive, severe psychomotor retardation, seizures and hypopigmented hair, which is characteristic of this condition."
      explanation: Directly supports hypopigmented hair as a downstream phenotype of the hair/pigment branch.
phenotypes:
- name: Neurodevelopmental delay
  description: >-
    Progressive neurodevelopmental impairment emerges in early infancy after a
    brief normal neonatal period.
  notes: >-
    Frequency band dropped: the cited evidence documents onset timing but no
    quantitative or frequency data. Orphanet (ORPHA:565) carries no HPO
    frequency row for HP:0012758; the related intellectual disability
    (HP:0001249) is classed Frequent and developmental regression (HP:0002376)
    Very frequent.
  phenotype_term:
    preferred_term: Neurodevelopmental delay
    term:
      id: HP:0012758
      label: Neurodevelopmental delay
  evidence:
  - reference: PMID:25281031
    reference_title: "Neurodevelopment and brain growth in classic Menkes disease is influenced by age and symptomatology at initiation of copper treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Untreated affected individuals suffer failure to thrive and neurodevelopmental delays that usually commence at 6-8 weeks of age."
    explanation: Documents the characteristic early-onset neurodevelopmental delay of untreated Menkes disease.
- name: Seizures
  frequency: VERY_FREQUENT
  description: >-
    Seizures often emerge during early infancy as neurodegeneration and brain
    copper deficiency progress.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:32714836
    reference_title: "Targeted next generation sequencing for newborn screening of Menkes disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At birth, affected Menkes infants appear healthy and typically develop normally for 6 to 10 weeks before seizures, failure to thrive, irreversible brain atrophy, and stalled neurodevelopment ensue."
    explanation: Identifies seizures as a characteristic early neurologic manifestation.
  - reference: ORPHA:565
    reference_title: "Menkes disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001250 | Seizure | Very frequent (99-80%)"
    explanation: >-
      Orphanet's curated HPO frequency annotation classifies seizure as Very
      frequent (99-80%) in Menkes disease; the band is reconciled from FREQUENT
      up to VERY_FREQUENT to match this source.
- name: Hypotonia
  frequency: VERY_FREQUENT
  description: >-
    Generalized hypotonia is a common early sign of central and peripheral
    nervous system involvement.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:22695177
    reference_title: "In utero copper treatment for Menkes disease associated with a severe ATP7A mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Despite this very early intervention with copper, the infant showed hypotonia, developmental delay, and electroencephalographic abnormalities and died of respiratory failure at 5.5 months of age."
    explanation: Documents hypotonia as a characteristic neurologic manifestation in severe Menkes disease.
  - reference: ORPHA:565
    reference_title: "Menkes disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001252 | Hypotonia | Very frequent (99-80%)"
    explanation: >-
      Orphanet's curated HPO frequency annotation classifies hypotonia as Very
      frequent (99-80%) in Menkes disease; the band is reconciled from FREQUENT
      up to VERY_FREQUENT to match this source (the prior case-report snippet
      documented the association but not a frequency).
- name: Failure to thrive
  description: >-
    Poor growth accompanies neurologic decline, feeding difficulty, and
    multisystem copper deficiency.
  notes: >-
    Frequency band dropped: the cited evidence documents onset timing but no
    quantitative or frequency data. Orphanet (ORPHA:565) carries no HPO
    frequency row for HP:0001508; the related feeding difficulties in infancy
    (HP:0008872) is classed Very frequent.
  phenotype_term:
    preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  evidence:
  - reference: PMID:25281031
    reference_title: "Neurodevelopment and brain growth in classic Menkes disease is influenced by age and symptomatology at initiation of copper treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Untreated affected individuals suffer failure to thrive and neurodevelopmental delays that usually commence at 6-8 weeks of age."
    explanation: Supports failure to thrive as a core early manifestation of untreated Menkes disease.
- name: Pili torti
  description: >-
    Characteristic brittle, twisted kinky hair reflects impaired copper
    delivery to hair-shaft and pigmentation enzymes.
  notes: >-
    Frequency band dropped: the evidence is qualitative ("main manifestations")
    with no frequency data, and pili torti is a best-fit HPO mapping of the
    quoted "kinky hair". Orphanet (ORPHA:565) carries no HP:0003777 row; the
    related woolly hair (HP:0002224) and sparse hair (HP:0008070) are classed
    Very frequent.
  phenotype_term:
    preferred_term: Pili torti
    term:
      id: HP:0003777
      label: Pili torti
  evidence:
  - reference: PMID:19888294
    reference_title: "Menkes disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Progressive neurodegeneration and connective tissue disturbances, together with the peculiar 'kinky' hair are the main manifestations."
    explanation: Supports kinky hair as a hallmark phenotype; pili torti is the best-fit HPO representation.
- name: Cutis laxa
  description: >-
    Wrinkled, redundant, inelastic skin results from reduced lysyl oxidase
    activity and deficient collagen and elastin cross-linking.
  notes: >-
    Frequency band dropped: the sole evidence is a single case report, which
    cannot establish a population frequency. Orphanet (ORPHA:565) carries no
    HP:0000973 row; the related hyperextensible skin (HP:0000974) and dry skin
    (HP:0000958) are classed Very frequent.
  phenotype_term:
    preferred_term: Cutis laxa
    term:
      id: HP:0000973
      label: Cutis laxa
  evidence:
  - reference: PMID:22695177
    reference_title: "In utero copper treatment for Menkes disease associated with a severe ATP7A mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "His skin was dry and wrinkled with a post-mature quality, and loose and redundant on the back and trunk."
    explanation: Directly documents the cutis laxa phenotype with loose, redundant, wrinkled skin in a Menkes disease patient.
- name: Cerebral atrophy
  description: >-
    Progressive cerebral atrophy develops during infancy as a consequence of
    copper-dependent enzyme deficiency and impaired neuronal energy metabolism.
  notes: >-
    Frequency band dropped: the cited evidence ("irreversible brain atrophy")
    documents the association but no quantitative or frequency data. Orphanet
    (ORPHA:565) carries no HPO frequency row for HP:0002059.
  phenotype_term:
    preferred_term: Cerebral atrophy
    term:
      id: HP:0002059
      label: Cerebral atrophy
  evidence:
  - reference: PMID:32714836
    reference_title: "Targeted next generation sequencing for newborn screening of Menkes disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At birth, affected Menkes infants appear healthy and typically develop normally for 6 to 10 weeks before seizures, failure to thrive, irreversible brain atrophy, and stalled neurodevelopment ensue."
    explanation: Documents irreversible brain atrophy as a characteristic feature of untreated Menkes disease.
- name: Arterial tortuosity
  description: >-
    Tortuous and elongated intracranial arteries reflect defective elastin
    cross-linking from lysyl oxidase deficiency.
  notes: >-
    Frequency band dropped: the cited evidence lists tortuous intracranial
    arteries as a "classic radiographic finding" but gives no quantitative or
    frequency data. Orphanet (ORPHA:565) carries no HP:0005116 row; the related
    abnormality of the carotid arteries (HP:0005344) and arterial stenosis
    (HP:0100545) are classed Frequent.
  phenotype_term:
    preferred_term: Arterial tortuosity
    term:
      id: HP:0005116
      label: Arterial tortuosity
  evidence:
  - reference: PMID:31198482
    reference_title: "Imaging findings of Menkes disease, a radiographic mimic of abusive trauma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The classic radiographic findings seen in Menke's disease have been documented and include wormian bones, diaphyseal and metaphyseal bone fractures, subdural hematomas, and tortuous intracranial arteries"
    explanation: Documents tortuous intracranial arteries as a classic radiographic finding in Menkes disease.
- name: Internal jugular vein phlebectasia
  frequency: OCCASIONAL
  description: >-
    Fusiform dilatation of the internal jugular vein occurs in approximately
    14% of Menkes disease patients and can present as neck masses.
  phenotype_term:
    preferred_term: Internal jugular vein phlebectasia
    term:
      id: HP:0002624
      label: Abnormal venous morphology
  evidence:
  - reference: PMID:32293788
    reference_title: "Neck masses due to internal jugular vein phlebectasia: Frequency in Menkes disease and literature review of 85 pediatric subjects."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our prospective results suggest that IJP occurs in approximately 14% (9/66) of Menkes disease patients and appears to be clinically benign with no specific medical or surgical actionability."
    explanation: Documents the frequency and clinical significance of internal jugular vein phlebectasia in Menkes disease.
- name: Bladder diverticulum
  frequency: OCCASIONAL
  description: >-
    Diverticula of the urinary bladder wall arise from connective tissue
    weakness due to impaired elastin and collagen cross-linking.
  phenotype_term:
    preferred_term: Bladder diverticulum
    term:
      id: HP:0000015
      label: Bladder diverticulum
  evidence:
  - reference: PMID:406641
    reference_title: "Bladder diverticula and Menkes' syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Multiple unusual diverticula of the bladder were observed in 3 of 4 children with Menkes' syndrome."
    explanation: Documents bladder diverticula as a urological finding in Menkes disease patients (a 4-patient series, too small to set a population frequency band).
  - reference: ORPHA:565
    reference_title: "Menkes disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000015 | Bladder diverticulum | Occasional (29-5%)"
    explanation: >-
      Orphanet's curated HPO frequency annotation classifies bladder
      diverticulum as Occasional (29-5%) in Menkes disease, supporting the
      OCCASIONAL band (the small case series alone cannot).
- name: Wormian bones
  frequency: FREQUENT
  description: >-
    Supernumerary intrasutural bones in the cranium reflect abnormal
    skeletal mineralization and connective tissue development.
  phenotype_term:
    preferred_term: Wormian bones
    term:
      id: HP:0002645
      label: Wormian bones
  evidence:
  - reference: PMID:20180106
    reference_title: "Long-term skeletal findings in Menkes disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Skeletal findings in infants with Menkes disease, the most characteristic of which are metaphyseal spurs, long-bone fractures and wormian bones, have been widely reported."
    explanation: Documents wormian bones as one of the most characteristic skeletal findings in Menkes disease.
  - reference: ORPHA:565
    reference_title: "Menkes disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002645 | Wormian bones | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO frequency annotation classifies wormian bones as
      Frequent (79-30%) in Menkes disease; the band is reconciled from
      OCCASIONAL up to FREQUENT to match this source.
- name: Subdural hemorrhage
  description: >-
    Fragile bridging veins due to lysyl oxidase deficiency predispose to
    subdural hemorrhage, which may be mistaken for non-accidental injury.
  notes: >-
    Frequency band dropped: the sole evidence is a single case report, which
    cannot establish a population frequency. Orphanet (ORPHA:565) carries no
    HP:0100309 row; the parent term intracranial hemorrhage (HP:0002170) is
    classed Very frequent.
  phenotype_term:
    preferred_term: Subdural hemorrhage
    term:
      id: HP:0100309
      label: Subdural hemorrhage
  evidence:
  - reference: PMID:12483361
    reference_title: "Massive subdural haematomas in Menkes disease mimicking shaken baby syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We present a case of Menkes disease complicated by progressive macrocephaly following the development of massive subdural haematomas."
    explanation: Documents subdural haematomas as a specific complication of Menkes disease that can mimic non-accidental injury.
- name: Fair hair
  description: >-
    Hair hypopigmentation results from impaired copper delivery to
    tyrosinase, the copper-dependent melanin biosynthesis enzyme.
  notes: >-
    Frequency band dropped: the cited evidence describes hypopigmented hair as
    "characteristic" but gives no quantitative or frequency data. Orphanet
    (ORPHA:565) carries no HP:0002286 row; the sibling term hypopigmentation of
    hair (HP:0005599) is classed Very frequent.
  phenotype_term:
    preferred_term: Fair hair
    term:
      id: HP:0002286
      label: Fair hair
  evidence:
  - reference: PMID:29675083
    reference_title: "Neuroimaging in Menkes Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These patients can present with failure to thrive, severe psychomotor retardation, seizures and hypopigmented hair, which is characteristic of this condition."
    explanation: Documents hypopigmented hair as a characteristic clinical feature of Menkes disease.
treatments:
- name: Copper histidinate
  description: >-
    Early subcutaneous copper histidinate partially bypasses the intestinal
    copper-transport defect and improves survival and neurodevelopment most
    effectively when started in the presymptomatic neonatal window. In January
    2026 the FDA granted first approval to copper histidinate injection
    (ZYCUBO) for Menkes disease in pediatric patients.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: copper histidinate therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: copper histidinate
      term:
        id: CHEBI:757183
        label: copper histidine
  target_phenotypes:
  - preferred_term: Neurodevelopmental delay
    term:
      id: HP:0012758
      label: Neurodevelopmental delay
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  - preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  target_mechanisms:
  - target: Systemic copper deficiency
    treatment_effect: RESTORES
    description: Early copper histidinate increases copper availability despite the ATP7A transport defect.
    evidence:
    - reference: PMID:25281031
      reference_title: "Neurodevelopment and brain growth in classic Menkes disease is influenced by age and symptomatology at initiation of copper treatment."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "These can normalize circulating blood levels and may replete brain copper depending on the molecular context, e.g., the severity of ATP7A mutation and potential presence of mosaicism."
      explanation: Supports copper histidinate as a treatment that restores systemic copper availability and can partially replete brain copper.
  - target: Brain copper deficiency
    treatment_effect: RESTORES
    description: Presymptomatic copper histidinate can partially replete brain copper before irreversible neurologic injury.
    evidence:
    - reference: PMID:25281031
      reference_title: "Neurodevelopment and brain growth in classic Menkes disease is influenced by age and symptomatology at initiation of copper treatment."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "These can normalize circulating blood levels and may replete brain copper depending on the molecular context, e.g., the severity of ATP7A mutation and potential presence of mosaicism."
      explanation: Supports copper histidinate as acting upstream of the neurologic branch when residual molecular context permits brain copper repletion.
  evidence:
  - reference: PMID:18256395
    reference_title: "Neonatal diagnosis and treatment of Menkes disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Among 12 newborns with positive screening tests who were treated early with copper, survival at a median follow-up of 4.6 years was 92%, as compared with 13% at a median follow-up of 1.8 years for a historical control group of 15 late-diagnosis and late-treatment patients."
    explanation: Supports markedly improved survival with early copper treatment relative to late-treated historical controls.
  - reference: PMID:25281031
    reference_title: "Neurodevelopment and brain growth in classic Menkes disease is influenced by age and symptomatology at initiation of copper treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We conclude that early copper histidine for Menkes disease is safe and efficacious, with treatment outcomes influenced by the timing of intervention, and ATP7A mutation."
    explanation: Confirms safety and efficacy of early copper histidine treatment and emphasizes the importance of presymptomatic treatment.
  - reference: PMID:42018271
    reference_title: "Copper Histidinate: Pediatric First Approval."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In January 2026, copper histidinate received its first approval in the USA by the U.S. Food and Drug Administration for the treatment of Menkes disease in pediatric patients."
    explanation: Documents the January 2026 FDA first approval of copper histidinate for pediatric Menkes disease, establishing it as an approved therapy rather than compounded-only.
- name: ATP7A gene therapy
  description: >-
    AAV-mediated ATP7A gene delivery remains investigational but has shown
    preclinical rescue in Menkes mouse models, particularly when combined with
    copper histidinate.
  therapeutic_modality: GENE_THERAPY
  treatment_term:
    preferred_term: gene therapy
    term:
      id: NCIT:C15238
      label: Gene Therapy
  target_mechanisms:
  - target: ATP7A-mediated copper export failure
    treatment_effect: RESTORES
    description: rAAV9-rsATP7A is intended to supply functional ATP7A and correct the initiating copper-transport defect.
    evidence:
    - reference: PMID:30090842
      reference_title: "Cerebrospinal Fluid-Directed rAAV9-rsATP7A Plus Subcutaneous Copper Histidinate Advance Survival and Outcomes in a Menkes Disease Mouse Model."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Based on these findings, and the absence of a large animal model, we propose cerebrospinal fluid-directed rAAV9-rsATP7A gene therapy plus subcutaneous copper histidinate as a potential therapeutic approach to cure or ameliorate Menkes disease."
      explanation: Supports ATP7A gene therapy as targeting the upstream ATP7A transport failure in a Menkes model.
  evidence:
  - reference: PMID:30090842
    reference_title: "Cerebrospinal Fluid-Directed rAAV9-rsATP7A Plus Subcutaneous Copper Histidinate Advance Survival and Outcomes in a Menkes Disease Mouse Model."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Based on these findings, and the absence of a large animal model, we propose cerebrospinal fluid-directed rAAV9-rsATP7A gene therapy plus subcutaneous copper histidinate as a potential therapeutic approach to cure or ameliorate Menkes disease."
    explanation: Supports ATP7A gene therapy as an experimental mechanistically targeted treatment emerging from mouse-model rescue studies.
biochemical:
- name: Serum copper
  presence: DECREASED
  notes: >-
    Low serum copper is a biochemical hallmark, though neonatal levels are
    normally low and not reliable for diagnosis until 6-8 weeks of age.
  evidence:
  - reference: PMID:22695177
    reference_title: "In utero copper treatment for Menkes disease associated with a severe ATP7A mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Affected individuals manifest low copper and ceruloplasmin levels in plasma or serum, as well as in cerebrospinal fluid."
    explanation: Confirms low serum copper as a core biochemical feature of Menkes disease.
- name: Serum ceruloplasmin
  presence: DECREASED
  notes: >-
    Low ceruloplasmin parallels low serum copper and reflects impaired
    hepatic copper delivery to ceruloplasmin apoenzyme.
  evidence:
  - reference: PMID:22695177
    reference_title: "In utero copper treatment for Menkes disease associated with a severe ATP7A mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Affected individuals manifest low copper and ceruloplasmin levels in plasma or serum, as well as in cerebrospinal fluid."
    explanation: Confirms low ceruloplasmin as a diagnostic biochemical marker.
- name: Plasma DOPA:DHPG ratio
  presence: INCREASED
  notes: >-
    Elevated ratios of DOPA to DHPG and DOPAC to DHPG reflect
    dopamine-beta-hydroxylase deficiency and provide a rapid neonatal
    diagnostic test with high sensitivity and specificity.
  evidence:
  - reference: PMID:24054147
    reference_title: "Catecholamine metabolites affected by the copper-dependent enzyme dopamine-beta-hydroxylase provide sensitive biomarkers for early diagnosis of menkes disease and viral-mediated ATP7A gene therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Partial deficiency of dopamine-beta-hydroxylase is a biochemical hallmark of this illness due to the normal role of ATP7A in delivery of copper as an enzymatic cofactor."
    explanation: Confirms dopamine-beta-hydroxylase deficiency as a sensitive and specific biomarker for Menkes disease.
  - reference: PMID:18256395
    reference_title: "Neonatal diagnosis and treatment of Menkes disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Exploiting the deficiency of a copper enzyme, dopamine-beta-hydroxylase, we prospectively evaluated the diagnostic usefulness of plasma neurochemical levels, assessed the clinical effect of early detection, and investigated the molecular bases for treatment outcomes."
    explanation: Establishes the utility of plasma catecholamine ratios as a diagnostic tool for early detection.
diagnosis:
- name: Plasma catecholamine analysis
  presence: POSITIVE
  description: >-
    Distinctive plasma neurochemical pattern with elevated DOPA:DHPG and
    DOPAC:DHPG ratios enables rapid neonatal diagnosis within hours.
  evidence:
  - reference: PMID:18256395
    reference_title: "Neonatal diagnosis and treatment of Menkes disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the neurochemical profiles were shown to have high sensitivity and specificity for detecting disease."
    explanation: Validates plasma catecholamine analysis as a highly sensitive and specific diagnostic test for Menkes disease.
- name: ATP7A molecular genetic testing
  presence: POSITIVE
  description: >-
    Targeted next-generation sequencing of ATP7A detects missense, nonsense,
    frameshift, splice-site, and copy-number variants with over 95%
    sensitivity from dried blood spots.
  evidence:
  - reference: PMID:32714836
    reference_title: "Targeted next generation sequencing for newborn screening of Menkes disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our results support proof-of-concept that primary DNA-based NBS would accurately detect Menkes disease, a disorder that fulfills Wilson and Jungner screening criteria and for which biochemical NBS is unavailable."
    explanation: Supports targeted NGS of ATP7A as a feasible first-tier newborn screening approach for Menkes disease.
has_subtypes:
- name: Classical Menkes disease
  description: >-
    Severe classical presentation with early-onset neurodegeneration, early
    seizures, and high mortality; truncating ATP7A variants are frequently
    associated with this subtype.
  genes:
  - preferred_term: ATP7A
    term:
      id: hgnc:869
      label: ATP7A
  evidence:
  - reference: DOI:10.1002/jimd.12590
    reference_title: "<scp><i>ATP7A</i></scp>‐related copper transport disorders: A systematic review and definition of the clinical subtypes"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Early seizures are specific for classical Menkes disease (CMD), that is characterized by early‐onset neurodegenerative disease with high mortality rates."
    explanation: Defines the severe classical subtype and its early seizure/neurodegenerative phenotype.
- name: Atypical Menkes disease
  description: >-
    Attenuated Menkes presentation with better survival than classical disease;
    ataxia is a distinguishing indicator in systematic subtype definitions.
  genes:
  - preferred_term: ATP7A
    term:
      id: hgnc:869
      label: ATP7A
  evidence:
  - reference: DOI:10.1002/jimd.12590
    reference_title: "<scp><i>ATP7A</i></scp>‐related copper transport disorders: A systematic review and definition of the clinical subtypes"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Ataxia is an independent indicator for atypical Menkes disease, that shows better survival rates than CMD."
    explanation: Defines atypical Menkes disease as an attenuated ATP7A-related subtype.
- name: Occipital horn syndrome
  subtype_term:
    preferred_term: occipital horn syndrome
    term:
      id: MONDO:0010572
      label: occipital horn syndrome
  description: >-
    Milder allelic variant of ATP7A deficiency with residual copper transport
    function. Characterized by connective tissue abnormalities including
    pathognomonic occipital exostoses, joint laxity, and bladder diverticula,
    with relatively mild or absent neurodegeneration. Affected individuals
    typically survive into adulthood.
  genes:
  - preferred_term: ATP7A
    term:
      id: hgnc:869
      label: ATP7A
  evidence:
  - reference: PMID:32528851
    reference_title: "Estimated birth prevalence of Menkes disease and ATP7A-related disorders based on the Genome Aggregation Database (gnomAD)."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Occipital horn syndrome and ATP7A-related distal motor neuropathy are allelic variants of Menkes disease that have less distinctive clincal and biochemical signs"
    explanation: Identifies occipital horn syndrome as an allelic variant of Menkes disease with milder presentation.
  - reference: DOI:10.1002/jimd.12590
    reference_title: "<scp><i>ATP7A</i></scp>‐related copper transport disorders: A systematic review and definition of the clinical subtypes"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bony exostoses, radial head dislocations, herniations and dental abnormalities are specific for occipital horn syndrome (OHS) that may further present with developmental delay and connective tissue manifestations."
    explanation: Adds systematic-review support for the distinguishing occipital horn syndrome phenotype.
- name: ATP7A-related distal motor neuropathy
  subtype_term:
    preferred_term: X-linked distal spinal muscular atrophy type 3
    term:
      id: MONDO:0010338
      label: X-linked distal spinal muscular atrophy type 3
  description: >-
    Mildest allelic variant caused by specific ATP7A missense mutations
    that selectively impair motor neuron function. Presents with
    progressive distal muscle weakness and atrophy without copper
    metabolism abnormalities.
  genes:
  - preferred_term: ATP7A
    term:
      id: hgnc:869
      label: ATP7A
  evidence:
  - reference: PMID:32528851
    reference_title: "Estimated birth prevalence of Menkes disease and ATP7A-related disorders based on the Genome Aggregation Database (gnomAD)."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Occipital horn syndrome and ATP7A-related distal motor neuropathy are allelic variants of Menkes disease that have less distinctive clincal and biochemical signs"
    explanation: Identifies ATP7A-related distal motor neuropathy as a milder allelic variant.
  - reference: CGGV:assertion_ec7c42f3-3cad-4020-aa75-cf103c5381ba-2023-01-10T170000.000Z
    reference_title: "ATP7A / X-linked distal spinal muscular atrophy type 3 (Moderate)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ATP7A | HGNC:869 | X-linked distal spinal muscular atrophy type 3 | MONDO:0010338 | XL | Moderate"
    explanation: >-
      ClinGen's Charcot-Marie-Tooth GCEP curates this subtype as its own ATP7A
      gene-disease entity, at Moderate rather than Definitive classification.
  - reference: CGGV:assertion_ec7c42f3-3cad-4020-aa75-cf103c5381ba-2023-01-10T170000.000Z
    reference_title: "ATP7A / X-linked distal spinal muscular atrophy type 3 (Moderate)"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "These patients present during adulthood with progressive distal muscle weakness and atrophy without clinical or biochemical characteristics of systemic copper deficiency."
    explanation: >-
      Supports this subtype's defining feature: an ATP7A phenotype that spares the
      systemic copper abnormalities of Menkes disease and occipital horn syndrome.
  review_notes: >-
    ClinGen applied its Lumping and Splitting criteria to ATP7A and split Menkes
    disease, occipital horn syndrome and distal spinal muscular atrophy into three
    gene-disease entities on molecular mechanism and phenotypic variability. dismech
    keeps them as `has_subtypes` rows of one ATP7A entry instead, because the split
    turns on residual transporter activity along the single mechanism this entry
    already models. The distinction is not lost: all three ClinGen entities are
    MONDO-anchored here, Menkes disease as this entry's own disease_term and the
    other two as subtype_terms on their rows.
datasets:
- accession: DOI:10.3390/genes12050744
  title: Whole-Exome Sequencing, Proteome Landscape, and Immune Cell Migration Patterns in a Clinical Context of Menkes Disease
  description: >-
    Multi-assay Menkes disease resource combining trio whole-exome sequencing,
    plasma proteomics, and immune-cell migration assays from an ATP7A-affected
    infant, his parents, and pediatric controls. The plasma proteomics arm is a
    directly reusable disease-biomarker dataset for systemic consequences of
    ATP7A dysfunction.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: PROTEOMICS
  sample_types:
  - preferred_term: blood plasma
    term:
      id: UBERON:0001969
      label: blood plasma
    tissue_term:
      preferred_term: blood plasma
      term:
        id: UBERON:0001969
        label: blood plasma
  sample_count: 7
  conditions:
  - Menkes disease plasma proteome
  - parental carrier/noncarrier comparison
  - pediatric control plasma proteome
  platform: LC-MS/MS with MaxQuant 1.6.2.6 analysis
  publication: PMID:34069220
  evidence:
  - reference: PMID:34069220
    reference_title: "Whole-Exome Sequencing, Proteome Landscape, and Immune Cell Migration Patterns in a Clinical Context of Menkes Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Compared with his parents and with child controls, 11 plasma proteins were upregulated and 59 downregulated in the patient."
    explanation: Supports this publication as a real human Menkes proteomics dataset with disease-versus-control molecular measurements.
clinical_trials:
- name: NCT00811785
  phase: PHASE_III
  status: COMPLETED
  description: >-
    Phase 3 study of daily injected copper histidine for Menkes disease,
    occipital horn syndrome, and unexplained copper deficiency, evaluating
    effectiveness, side effects, dosage, and molecular predictors of response.
  target_phenotypes:
  - preferred_term: Neurodevelopmental delay
    term:
      id: HP:0012758
      label: Neurodevelopmental delay
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  - preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  evidence:
  - reference: clinicaltrials:NCT00811785
    reference_title: "Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients will receive a prescribed dose of copper histidine, which will be administered daily as an injection."
    explanation: ClinicalTrials.gov documents the copper histidine intervention used in this Menkes disease treatment study.
classifications:
  harrisons_chapter:
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
  - classification_value: NEUROLOGIC
  - classification_value: IMMUNE_RHEUMATOLOGIC
  icimd_category:
  - classification_value: copper_metabolism
    notes: >-
      ICIMD (Ferreira et al. 2021, PMID:33340416): group "Copper" under
      category "Disorders of trace elements and metals". Menkes disease is
      ATP7A-related systemic copper deficiency, the ATP7B/Wilson paralog acting
      in the opposite direction.
mappings:
  icd10cm_mappings:
  - term:
      id: ICD10CM:E83.00
      label: Disorder of copper metabolism, unspecified
    mapping_predicate: skos:closeMatch
    mapping_source: ICD-10-CM
    mapping_justification: ICD-10-CM E83.00 is the closest code for Menkes disease as a copper metabolism disorder.
animal_models:
- name: Brindled mouse (Atp7a Mo-br)
  species: Mouse
  genotype: Atp7a<Mo-br>/Y (hemizygous male)
  background: C57BL/6-Atp7a<Mo-br>/J
  alleles:
  - Atp7a<Mo-br>
  genes:
  - preferred_term: ATP7A
    term:
      id: hgnc:869
      label: ATP7A
  publication: PMID:16371425
  description: >-
    The brindled allele of the mouse mottled series, the long-standing Menkes model.
    The study cited here uses it to show that ATP7A is required to load copper onto
    a secretory cuproenzyme in the trans-Golgi network: aortic and fibroblast SOD3
    loses specific activity while cytosolic SOD1 does not, and copper supplementation
    partially restores it. That rescue is the point of curating this model against
    an amount-versus-activity node - the enzyme protein is present, and what is
    missing is its metal cofactor.
  modeled_mechanisms:
  - target: ATP7A-mediated copper export failure
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      A mutant Atp7a allele reproduces the failure to deliver copper through the
      secretory pathway, assayed in vascular tissue and cultured fibroblasts.
    limitations: >-
      Mo-br is a mouse mottled allele, not a human ATP7A variant, and the copper
      delivery step is assayed here only for the trans-Golgi/secretory route to SOD3.
      The study is a vascular-biology investigation rather than a Menkes natural-history
      study.
    readouts:
    - name: SOD3 specific activity in aorta and cultured fibroblasts
      target: ATP7A-mediated copper export failure
      direction: DECREASED
      interpretation: >-
        A specific-activity measurement that falls without the enzyme protein being
        lost, and is partially restored by adding copper - the cofactor-deficiency
        pattern in which activity and amount dissociate. Cytosolic SOD1 is unaffected,
        which localizes the lesion to the secretory route ATP7A serves.
      evidence:
      - reference: PMID:16371425
        reference_title: 'Essential role for the Menkes ATPase in activation of extracellular
          superoxide dismutase: implication for vascular oxidative stress.'
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: Aortas and cultured fibroblasts from MNK mutant (MNK(mut)) mice showed
          a marked decrease in specific activity of SOD3, but not SOD1 (cytosolic
          form), which was partially restored by copper addition.
        explanation: Reports the cuproenzyme specific-activity deficit and its rescue
          by copper, which together establish the defect as cofactor loading rather
          than enzyme loss.
    evidence:
    - reference: PMID:16371425
      reference_title: 'Essential role for the Menkes ATPase in activation of extracellular
        superoxide dismutase: implication for vascular oxidative stress.'
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: In conclusion, vascular MNK plays an essential role in full activity
        of SOD3 through transporting copper to SOD3 in the TGN, thereby regulating
        O2*- levels in the vasculature.
      explanation: States the transporter-to-cuproenzyme dependency that makes this
        mutant informative for the copper export node.
  - target: Cuproenzyme deficiency and neurodevelopmental injury
    relationship: PARTIALLY_RECAPITULATES
    fidelity: LOW
    description: >-
      Demonstrates cuproenzyme inactivation downstream of ATP7A loss, with the
      expected oxidative consequence when the cuproenzyme is an antioxidant.
    limitations: >-
      The cuproenzyme measured is vascular SOD3, not the neuronal cuproenzymes
      (cytochrome c oxidase, dopamine beta-hydroxylase, peptidylglycine alpha-amidating
      monooxygenase) through which Menkes disease produces its neurodevelopmental
      phenotype. No neurologic or developmental outcome is assessed in this study,
      so the model supports the cuproenzyme half of this node and says nothing about
      the injury half.
    readouts:
    - name: Vascular superoxide anion level
      target: Cuproenzyme deficiency and neurodevelopmental injury
      direction: INCREASED
      interpretation: >-
        The oxidative consequence of losing an extracellular cuproenzyme's activity
        in aortic tissue.
      evidence:
      - reference: PMID:16371425
        reference_title: 'Essential role for the Menkes ATPase in activation of extracellular
          superoxide dismutase: implication for vascular oxidative stress.'
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: Aortas of MNK(mut) mice revealed a decrease in activity of SOD3,
          but not SOD1, in association with a robust increase in O2*- levels.
        explanation: Links the cuproenzyme activity loss to a measured rise in superoxide.
    evidence:
    - reference: PMID:16371425
      reference_title: 'Essential role for the Menkes ATPase in activation of extracellular
        superoxide dismutase: implication for vascular oxidative stress.'
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Here we show that MNK was highly expressed in the various vascular
        tissues and cells.
      explanation: Establishes that the transporter is expressed where the cuproenzyme
        deficit was measured, which is what makes this mutant informative for the
        cuproenzyme node - noting the measurement is vascular, not neuronal.
- name: Viable brindled mouse (Atp7a Mo-vbr)
  species: Mouse
  genotype: Atp7a<Mo-vbr>/Y (hemizygous male)
  alleles:
  - Atp7a<Mo-vbr>
  genes:
  - preferred_term: ATP7A
    term:
      id: hgnc:869
      label: ATP7A
  publication: PMID:9342151
  description: >-
    A viable mottled allele assessed by 31P magnetic resonance spectroscopy and
    enzymology as a model of mitochondrial impairment. Two respiratory-chain
    activities are reduced in a tissue-specific pattern - succinate-cytochrome c
    reductase in muscle and the copper-dependent cytochrome oxidase in brain -
    and phosphocreatine recovery after exercise is slowed. Only cytochrome
    oxidase (complex IV) is a cuproenzyme; succinate-cytochrome c reductase
    spans complexes II and III, which use flavin, iron-sulfur clusters and
    hemes, so the muscle deficit is not itself evidence of cuproenzyme failure.
  modeled_mechanisms:
  - target: Cuproenzyme deficiency and neurodevelopmental injury
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: >-
      Reduced cytochrome oxidase activity in brain is the cuproenzyme deficit that
      this node names, measured directly in the tissue where Menkes disease causes
      neurodegeneration.
    limitations: >-
      The study measures enzyme activities and energetics, not neurodevelopmental
      outcome, so it substantiates the cuproenzyme arm rather than the injury arm.
      The deficits are tissue-restricted - cytochrome oxidase is reduced in brain but
      not muscle - so a single-tissue assay does not generalize across organs. Mo-vbr
      is a mouse allele, not a human ATP7A variant.
    readouts:
    - name: Cytochrome oxidase activity in brain
      target: Cuproenzyme deficiency and neurodevelopmental injury
      direction: DECREASED
      interpretation: >-
        Direct catalytic-activity measurement of a copper-dependent respiratory-chain
        enzyme in the affected tissue.
      evidence:
      - reference: PMID:9342151
        reference_title: 'A 31P-magnetic resonance spectroscopy and biochemical study
          of the mo(vbr) mouse: potential model for the mitochondrial encephalomyopathies.'
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: The maximal activity of succinate-cytochrome c reductase was significantly
          reduced in mo(vbr) muscle compared to controls, whereas cytochrome oxidase
          activity was only reduced in mo(vbr) brain.
        explanation: Reports both respiratory-chain activity deficits and their tissue
          specificity.
    evidence:
    - reference: PMID:9342151
      reference_title: 'A 31P-magnetic resonance spectroscopy and biochemical study of
        the mo(vbr) mouse: potential model for the mitochondrial encephalomyopathies.'
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: We conclude that mo(vbr) brain and muscle tissue have biochemical abnormalities
        consistent with mitochondrial impairment.
      explanation: The authors' summary of the enzymatic and energetic deficits that
        make this mutant informative for the cuproenzyme node.
references:
- reference: PMID:20301586
  title: ATP7A-Related Copper Transport Disorders.
  tags:
  - GeneReviews
  findings: []

📚

References & Deep Research

References

1

PMID:20301586

ATP7A-Related Copper Transport Disorders.

No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Falcon ▸

Menkes Disease (ATP7A-related copper transport disorder) — Comprehensive Disease Characteristics Report

Edison Scientific Literature 33 citations 2026-04-25T22:37:53.701716

Menkes Disease (ATP7A-related copper transport disorder) — Comprehensive Disease Characteristics Report

1. Disease information

Overview (current understanding)

Menkes disease (MD) is a rare, typically male-infantile, X-linked disorder of systemic copper deficiency caused by pathogenic variants in ATP7A, which encodes a copper-transporting P-type ATPase required for copper distribution to the secretory pathway and copper-dependent enzymes. The disorder is characterized by progressive neurodegeneration, seizures, hypotonia/developmental regression, abnormal hair (classically hypopigmented/brittle/kinky), and connective-tissue/vascular and skeletal abnormalities. (wiecek2024disordersofcopper pages 7-8, fujisawa2022earlyclinicalsigns pages 1-2, vairo2019asystematicreview pages 1-6)

Key identifiers

OMIM: Menkes disease #309400 (wiecek2024disordersofcopper pages 7-8, feyter2023atp7a‐relatedcoppertransport pages 14-18)
OMIM (allelic disorders within ATP7A spectrum): Occipital horn syndrome (OHS) #304150; X-linked distal spinal muscular atrophy type 3 (SMAX3) #300489 (feyter2023atp7a‐relatedcoppertransport pages 14-18)
MeSH / ICD-10 / ICD-11 / Orphanet / MONDO: Not retrievable from the available full-text evidence in this run; should be added from OMIM/Orphanet/MeSH/MONDO registries directly (not primary literature).

Synonyms / alternative names

Reported synonyms include Kinky Hair Disease, Trichopoliodystrophy, and Steely Disease. (wiecek2024disordersofcopper pages 7-8)

Evidence source type

This report is derived from aggregated disease-level resources and primary/secondary literature (systematic reviews, guidelines, case series/case reports) rather than EHR-derived cohorts. (feyter2023atp7a‐relatedcoppertransport pages 18-21, vairo2019asystematicreview pages 1-6, zhu2024brainandthe pages 1-2)

2. Etiology

Disease causal factors

Genetic cause: Pathogenic variants in ATP7A (Xq13.3) cause Menkes disease and related ATP7A-spectrum phenotypes. (fujisawa2022earlyclinicalsigns pages 1-2, wiecek2024disordersofcopper pages 7-8)
Variant landscape: >350 disease-causing ATP7A variants have been reported (missense, nonsense, splice-site, indels, and larger events), with approximately one-third arising de novo. (wiecek2024disordersofcopper pages 7-8)

Risk factors

Primary risk factor: Inheritance of a pathogenic ATP7A variant (X-linked). Most affected individuals are male; female presentations are unusual but can occur in special genetic contexts (e.g., unfavorable X-inactivation). (wiecek2024disordersofcopper pages 10-11)

Protective factors

No validated genetic or environmental protective factors were identified in the retrieved evidence.

Gene–environment interactions

Not established for Menkes disease in the retrieved evidence; the phenotype is primarily determined by ATP7A functional residual activity and timing of therapeutic copper delivery. (tumer2017a37‐year‐oldmenkes pages 1-4, fujisawa2022earlyclinicalsigns pages 1-2)

3. Phenotypes (clinical spectrum)

ATP7A-related clinical subtypes (2023 systematic re-definition)

A systematic review curated 162 molecularly confirmed individuals and classified them as: classical Menkes disease (CMD) 62.3%, atypical/attenuated Menkes disease (AMD) 11.1%, OHS 22.6%, and SMAX3 3.7%. (feyter2023atp7a‐relatedcoppertransport pages 18-21)

Key differentiators: * CMD: seizures as initial symptom or seizures before 3 months are highly suggestive; severe neurodevelopmental course and early mortality. (feyter2023atp7a‐relatedcoppertransport pages 24-27) * AMD: ataxia is relatively specific; lower early-demise risk than CMD. (feyter2023atp7a‐relatedcoppertransport pages 24-27) * OHS: occipital horns are pathognomonic; radial head dislocations, herniations, and dental abnormalities support the diagnosis; connective tissue/urologic issues common. (feyter2023atp7a‐relatedcoppertransport pages 24-27) * SMAX3: late-onset distal motor neuropathy without major neuromotor delay; defined by neurophysiology (EMG). (feyter2023atp7a‐relatedcoppertransport pages 24-27)

Common phenotypes (type → characteristics → suggested HPO)

Below are representative phenotypes strongly supported in the retrieved clinical literature; frequencies are variably reported.

Neurodevelopmental delay/regression (symptom/sign): typical onset in early infancy; often progressive. Suggested HPO: Global developmental delay (HP:0001263), Developmental regression (HP:0002376). (vairo2019asystematicreview pages 1-6)
Seizures/epileptic encephalopathy (symptom/sign): often begin around 2–3 months; may be severe/intractable in classic disease. Suggested HPO: Seizures (HP:0001250), Infantile spasms (HP:0012469). (wiecek2024disordersofcopper pages 8-10, fujisawa2022earlyclinicalsigns pages 1-2)
Hypotonia (clinical sign): early and common. Suggested HPO: Hypotonia (HP:0001252). (vairo2019asystematicreview pages 1-6, feyter2023atp7a‐relatedcoppertransport pages 24-27)
Hair abnormalities (physical manifestation): hypopigmented/brittle/kinky hair in CMD; coarse hair more typical in OHS. Suggested HPO: Pili torti (HP:0003777), Abnormal hair (HP:0001595), Hypopigmented hair (HP:0005558). (feyter2023atp7a‐relatedcoppertransport pages 24-27)
Connective tissue/vascular involvement: vascular tortuosity and bladder diverticula can occur across subtypes and have high complication risk. Suggested HPO: Arterial tortuosity (HP:0005116), Bladder diverticulum (HP:0000017). (feyter2023atp7a‐relatedcoppertransport pages 1-5, feyter2023atp7a‐relatedcoppertransport pages 24-27)
Skeletal abnormalities: wormian bones, metaphyseal changes; OHS with occipital horns/exostoses. Suggested HPO: Wormian bones (HP:0002645), Metaphyseal widening (HP:0005014), Exostoses (HP:0100777), Occipital horn (HP:0002517). (zhu2024brainandthe pages 1-2, feyter2023atp7a‐relatedcoppertransport pages 24-27)

Quality of life impact (recent data)

A 2023 cross-sectional caregiver study (n=16) using PedsQL 4.0 and the PedsQL Family Impact Module reported very low child HRQOL: overall mean 29.14 (SD 14.73) on a 0–100 scale, with physical functioning particularly low (10.55, SD 10.26). Family impact was substantial, with mean overall family-impact rating 44.16 (SD 17.40) and low scores in worry and daily activities domains. (rozensztrauch2023healthrelatedqualityof pages 1-2, rozensztrauch2023healthrelatedqualityof pages 7-8, rozensztrauch2023healthrelatedqualityof pages 4-5)

4. Genetic / molecular information

Causal gene

ATP7A (copper-transporting P-type ATPase) is the causal gene in Menkes disease. (fujisawa2022earlyclinicalsigns pages 1-2)

Pathogenic variant classes and functional consequences

Menkes disease is driven largely by loss-of-function or severely hypomorphic ATP7A variants. Truncating variants are enriched in CMD, while splice-site/intronic variants (allowing low residual expression) are enriched in OHS; SMAX3 is linked to missense variants in/near transmembrane helices essential for copper transport. (feyter2023atp7a‐relatedcoppertransport pages 24-27)

Modifier genes / epigenetics / chromosomal abnormalities

No validated modifier genes or disease-specific epigenetic signatures were identified in the retrieved evidence.

5. Environmental information

Menkes disease is primarily genetic. No environmental/lifestyle/infectious causal factors were identified in the retrieved evidence.

6. Mechanism / pathophysiology

Core causal chain (systemic copper deficiency → enzyme dysfunction → multisystem phenotype)

ATP7A dysfunction impairs copper export and distribution, leading to systemic copper deficiency, low brain copper, and reduced activity of multiple copper-dependent enzymes (including dopamine β-hydroxylase, lysyl oxidase, and cytochrome c oxidase), which in turn drives neurological impairment, connective tissue fragility, and vascular/skeletal manifestations. (wiecek2024disordersofcopper pages 7-8, fujisawa2022earlyclinicalsigns pages 1-2)

Upstream vs downstream mechanisms

Upstream: impaired ATP7A-dependent copper transport and delivery to the secretory pathway (Golgi incorporation into cuproenzymes). (fujisawa2022earlyclinicalsigns pages 1-2)
Downstream: impaired catecholamine biosynthesis (via dopamine β-hydroxylase), defective connective tissue crosslinking (lysyl oxidase), mitochondrial respiratory defects (cytochrome c oxidase), contributing to neurodegeneration and systemic tissue vulnerability. (wiecek2024disordersofcopper pages 7-8)

Suggested ontology terms

GO Biological Process (examples): copper ion transport; cellular copper ion homeostasis; catecholamine biosynthetic process; mitochondrial electron transport chain; extracellular matrix organization.
Cell types (CL examples): neurons (incl. noradrenergic neurons), oligodendrocytes (myelination context), enterocytes (intestinal copper handling), vascular smooth muscle cells/fibroblasts (connective tissue phenotype).

7. Anatomical structures affected

Organ systems (supported)

Central nervous system: progressive neurodegeneration, brain atrophy, delayed myelination, seizures. (wiecek2024disordersofcopper pages 8-10, zhu2024brainandthe pages 1-2)
Vascular system: intracranial arterial tortuosity; risk of vascular complications. (zhu2024brainandthe pages 1-2, feyter2023atp7a‐relatedcoppertransport pages 24-27)
Skeletal/connective tissue: wormian bones, metaphyseal changes; occipital horns in OHS. (zhu2024brainandthe pages 1-2, feyter2023atp7a‐relatedcoppertransport pages 24-27)

Imaging-supported anatomical localization (UBERON suggestions)

Brain (UBERON:0000955), cerebellum (UBERON:0002037), basal ganglia (UBERON:0002420), intracranial arteries (UBERON:0001637), skull (UBERON:0003129), long bones (UBERON:0002384).

8. Temporal development (onset and progression)

Typical onset: early infancy. Neurological disturbances often begin around 2–3 months, and early hair abnormalities can appear by 1–2 months. (wiecek2024disordersofcopper pages 8-10, fujisawa2022earlyclinicalsigns pages 1-2)
Progression: typically progressive with neurodevelopmental regression and multisystem complications in CMD. (vairo2019asystematicreview pages 1-6)
Critical period for intervention: neonatal/presymptomatic window is repeatedly emphasized for copper therapy benefit. (vairo2019asystematicreview pages 1-6, fujisawa2022earlyclinicalsigns pages 1-2)

9. Inheritance and population

Inheritance

X-linked recessive (primary). (fujisawa2022earlyclinicalsigns pages 1-2, vairo2019asystematicreview pages 1-6)

Epidemiology (recently cited estimates)

Reported incidence/prevalence varies by geography: * Europe incidence estimate: ~1 in 300,000 live births. (vairo2019asystematicreview pages 1-6) * Australia: reports as high as 1 in 40,000. (vairo2019asystematicreview pages 1-6) * Japan incidence: 1 in 360,000 (reported in a 2022 review of early signs/treatment). (fujisawa2022earlyclinicalsigns pages 1-2) * Prevalence estimate: ~1:140,000 males (review source). (wiecek2024disordersofcopper pages 7-8)

10. Diagnostics

Laboratory tests and biomarkers

Serum copper and ceruloplasmin: classically low, but unreliable for neonates due to low levels in healthy newborns. One pediatric review recommends measuring after the third week of life. (wiecek2024disordersofcopper pages 10-11, zhu2024brainandthe pages 1-2)
Neonatal plasma catecholamines (guideline-level evidence): A systematic-review guideline reports that plasma catecholamine analysis supports neonatal diagnosis, with reported diagnostic thresholds of dopamine/norepinephrine ratio >0.2 and DOPAC/DHPG ratio >5, with 100% sensitivity and specificity in small neonatal cohorts. (vairo2019asystematicreview pages 6-10, vairo2019asystematicreview pages 18-22)

Direct abstract-quote style statements present in the evidence include: * “analysis of plasma catecholamine levels is accurate for neonatal diagnosis of Menkes disease” (systematic review/guideline). (vairo2019asystematicreview pages 1-6) * “serum copper and ceruloplasmin levels are not reliable diagnostic biomarkers due to the low concentrations in healthy newborns” (case report/review). (zhu2024brainandthe pages 1-2)

Imaging

A 2024 BMC Pediatrics case report/literature review emphasizes characteristic imaging patterns: * Brain MRI/MRA: intracranial vascular tortuosity, cerebral/cerebellar atrophy, delayed myelination/white-matter changes, basal ganglia abnormalities. (zhu2024brainandthe pages 1-2, zhu2024brainandthe media f56ccfea) * Skeletal radiographs: wormian bones, rib flaring, metaphyseal spurring, periosteal reactions. (zhu2024brainandthe pages 1-2, zhu2024brainandthe media f2ce26df)

Genetic testing

Molecular confirmation by identifying a pathogenic ATP7A variant is central; ACMG-based variant classification is used in clinical reporting. (zhu2024brainandthe pages 1-2)

Prenatal diagnosis and counseling

Prenatal genetic diagnosis is feasible in families with a prior affected child; counseling should consider possibilities such as germline mosaicism when maternal carrier status is not detected. (vairo2019asystematicreview pages 1-6, vairo2019asystematicreview pages 18-22)

11. Outcome / prognosis

Natural history (untreated)

Classic Menkes disease has a poor prognosis, often leading to death in early childhood (commonly cited as before ~3 years). (fujisawa2022earlyclinicalsigns pages 1-2, vairo2019asystematicreview pages 1-6)

Subtype-stratified mortality (systematic review)

In the 162-person systematic review: * CMD mortality 40.6%, mean age at death 2.3 years. * OHS mortality 13.5%, mean age at death 25.3 years. Infectious disease was the most common cause of death in CMD. (feyter2023atp7a‐relatedcoppertransport pages 18-21)

12. Treatment

Standard disease-modifying therapy: parenteral copper histidine / copper histidinate

Evidence syntheses and clinical programs consistently identify parenteral copper-histidine / copper histidinate as the main disease-modifying therapy, with benefit strongest when started in the neonatal/presymptomatic period.

Guideline conclusion (systematic review): “treatment with copper-histidine is effective to increase survival and reduce neurologic burden of the disease if initiated in the neonatal period.” (vairo2019asystematicreview pages 1-6)
Quantitative survival comparisons summarized in the guideline review include improved survival with neonatal initiation (e.g., 62.5% vs 8.3–37.5%, and 92% vs 13% in small cohorts/historical comparisons) and low NNTs to prevent a death (reported as 2.6 and 1.27 across datasets). (vairo2019asystematicreview pages 10-14)
Treatment response is heterogeneous and may depend on residual ATP7A function; a long-surviving treated individual reached 37 years, associated with early and sustained parenteral copper and a missense variant consistent with residual transport function, although long-term renal toxicity occurred. (tumer2017a37‐year‐oldmenkes pages 1-4)

CHEBI suggestion: copper(II) (CHEBI:29036); copper histidinate / copper bis(histidinate) (map to appropriate CHEBI entry in downstream curation).

MAXO suggestions: copper supplementation therapy; subcutaneous drug administration; parenteral trace-element replacement.

Supportive care (real-world implementation)

Supportive management includes seizure control, nutritional support/feeding tube placement, infection prevention, and management of urologic complications such as bladder diverticula. (zhu2024brainandthe pages 4-6)

Emerging/experimental therapies (latest research emphasis)

CNS-directed AAV gene therapy (preclinical): In a severe mouse model, CSF-delivered rAAV9 encoding a compact ATP7A (rsATP7A) combined with subcutaneous copper histidinate produced 53.3% long-term (≥300-day) survival versus 0% with either treatment alone, with improvements in brain copper, neurochemistry, and neurobehavior. (haddad2018cerebrospinalfluiddirectedraav9rsatp7a pages 1-2)

13. Prevention

Primary prevention: not applicable in a genetic disorder, aside from reproductive options.
Secondary prevention (early detection): the key preventive strategy for morbidity/mortality is early/presymptomatic diagnosis enabling neonatal copper therapy. Plasma catecholamine ratios are described as accurate for neonatal diagnosis in guideline synthesis. (vairo2019asystematicreview pages 6-10, vairo2019asystematicreview pages 1-6)
Genetic counseling / reproductive prevention: prenatal genetic diagnosis is feasible in families with a known case; counseling should account for potential germline mosaicism. (vairo2019asystematicreview pages 18-22)

14. Other species / natural disease

The retrieved evidence does not provide natural (non-laboratory) Menkes-like disease in other species.

15. Model organisms

A severe Menkes mouse model has been used to test combined copper replacement and CNS gene therapy strategies, demonstrating major survival and neuropathology improvements with combined CSF rAAV9-rsATP7A plus copper histidinate. (haddad2018cerebrospinalfluiddirectedraav9rsatp7a pages 1-2)

Current applications and real-world implementations (ClinicalTrials.gov)

NCT00001262 (NIH; started 1990; completed 2013): “Early Copper Histidine Therapy in Menkes Disease,” Phase 1/2 single-group, n=60, presymptomatic newborns; primary outcome developmental milestones at 36 months or death. (NCT00001262 chunk 1)
NCT00811785 (Cyprium; completed 2020): Phase 3, n=93, daily subcutaneous copper histidinate up to 3 years; survival comparisons for classic Menkes and neurologic outcomes for related phenotypes. (NCT00811785 chunk 1)
NCT04074512 (Sentynl; expanded access; “approved for marketing” listing): provides subcutaneous copper histidinate (CUTX-101) for US pediatric patients <6 years, including newly diagnosed individuals under defined biochemical/genetic criteria. (NCT04074512 chunk 1)

Expert opinion / analysis (authoritative synthesis)

A 2019 evidence-based guideline concludes copper-histidine can be disease-modifying only when initiated in the neonatal period, and emphasizes the inadequacy of relying on newborn serum copper/ceruloplasmin for early diagnosis, motivating use of neonatal catecholamine testing and prenatal diagnosis in known families. (vairo2019asystematicreview pages 1-6)
A 2023 systematic review highlights that counseling is challenging due to overlap among ATP7A phenotypes, limited predictive biomarkers, and weak genotype–phenotype correlation; it proposes practical subtype criteria and reports substantial differences in mortality between CMD and OHS. (feyter2023atp7a‐relatedcoppertransport pages 18-21, feyter2023atp7a‐relatedcoppertransport pages 24-27)

Reference summary table

The following table consolidates identifiers, subtype definitions, diagnostic biomarkers, epidemiology, and prognosis.

Domain	Key data	Quantitative details	DOI / URL / Year	Supporting citations
Disease / identifiers	Menkes disease; OMIM #309400; ATP7A-related copper transport disorder spectrum includes classical Menkes disease (CMD), atypical Menkes disease (AMD), occipital horn syndrome (OHS; OMIM #304150), and X-linked distal spinal muscular atrophy type 3 / SMAX3 (OMIM #300489)	ATP7A spans ~140 kb with 23 exons; review cohort included 162 molecularly confirmed individuals	De Feyter et al., J Inherit Metab Dis 2023; DOI: https://doi.org/10.1002/jimd.12590	(feyter2023atp7a‐relatedcoppertransport pages 1-5, feyter2023atp7a‐relatedcoppertransport pages 18-21, feyter2023atp7a‐relatedcoppertransport pages 14-18)
Synonyms / alternative names	Kinky Hair Disease, Trichopoliodystrophy, Steely Disease; OHS also described as X-linked cutis laxa variant	Primarily affects male infants; female cases rare but reported due to unusual X-inactivation or chromosomal mechanisms	Więcek & Paprocka 2024: https://doi.org/10.3390/metabo14010038; Matsumoto et al. 2024: https://doi.org/10.1038/s41598-023-50668-2	(wiecek2024disordersofcopper pages 7-8, wiecek2024disordersofcopper pages 10-11, wiecek2024disordersofcopper pages 8-10)
Inheritance / causal gene	X-linked recessive disorder caused by pathogenic variants in ATP7A (ATPase copper transporting alpha; Xq13.3), encoding a copper-transporting P-type ATPase	>350 disease-causing variants reported; about one-third de novo	Więcek & Paprocka 2024: https://doi.org/10.3390/metabo14010038; Fujisawa et al. 2022: https://doi.org/10.1016/j.ymgmr.2022.100849	(wiecek2024disordersofcopper pages 7-8, wiecek2024disordersofcopper pages 10-11, fujisawa2022earlyclinicalsigns pages 1-2)
Major subtypes	CMD: early-onset neurodegeneration with early seizures, severe course. AMD: attenuated overlap phenotype, ataxia is a key discriminator, better survival. OHS: milder connective-tissue-predominant phenotype with occipital horns, radial head dislocations, hernias, bladder diverticula, dental abnormalities. SMAX3: late-onset distal motor neuropathy without intellectual disability or occipital horns	Distribution in 162-patient review: CMD 101/162 (62.3%); AMD 18/162 (11.1%); OHS 37/162 (22.6%); SMAX3 6/162 (3.7%)	De Feyter et al. 2023: https://doi.org/10.1002/jimd.12590	(feyter2023atp7a‐relatedcoppertransport pages 1-5, feyter2023atp7a‐relatedcoppertransport pages 18-21, feyter2023atp7a‐relatedcoppertransport pages 14-18, feyter2023atp7a‐relatedcoppertransport pages 24-27)
Hallmark biochemical diagnosis	Low serum copper and ceruloplasmin are classic findings, but both are unreliable in healthy newborns/early infancy; ceruloplasmin may be more sensitive than serum copper for severity discrimination among ATP7A phenotypes	Measure serum copper / ceruloplasmin after the 3rd week of life in one review; conventional blood copper / ceruloplasmin become more diagnostically useful only after ~3 months in guideline review	Vairo et al. 2019: https://doi.org/10.1016/j.ymgme.2018.12.005; Więcek & Paprocka 2024: https://doi.org/10.3390/metabo14010038; Zhu et al. 2024: https://doi.org/10.1186/s12887-024-04885-x	(wiecek2024disordersofcopper pages 10-11, vairo2019asystematicreview pages 6-10, vairo2019asystematicreview pages 1-6, feyter2023atp7a‐relatedcoppertransport pages 27-31, zhu2024brainandthe pages 1-2)
Plasma catecholamine biomarkers	Neonatal plasma catecholamines are highlighted as accurate early biomarkers because dopamine-β-hydroxylase is copper-dependent	Diagnostic thresholds reported: dopamine / norepinephrine ratio >0.2 and dihydroxyphenylacetic acid / dihydroxyphenylglycol ratio >5; reported 100% sensitivity and 100% specificity in small neonatal cohorts summarized by guideline	Vairo et al. 2019: https://doi.org/10.1016/j.ymgme.2018.12.005	(vairo2019asystematicreview pages 6-10, vairo2019asystematicreview pages 18-22)
Epidemiology	Rare disorder with region-specific estimates	Europe: incidence about 1 in 300,000 live births; Australia: reports up to 1 in 40,000; Japan: incidence 1 in 360,000; prevalence estimate in one review about 1:140,000 males	Vairo et al. 2019: https://doi.org/10.1016/j.ymgme.2018.12.005; Fujisawa et al. 2022: https://doi.org/10.1016/j.ymgmr.2022.100849; Więcek & Paprocka 2024: https://doi.org/10.3390/metabo14010038	(wiecek2024disordersofcopper pages 7-8, fujisawa2022earlyclinicalsigns pages 1-2, vairo2019asystematicreview pages 1-6)
Typical onset / hallmark clinical picture	Onset in early infancy with abnormal hair, hypotonia, developmental regression, seizures, connective-tissue and vascular abnormalities, feeding difficulties, autonomic dysfunction; imaging often shows cerebral/cerebellar atrophy and tortuous intracranial vessels	First sign can be sparse/lustreless hair at 1–2 months; neurological disturbances often begin at 2–3 months; typical diagnosis at 3–6 months; mean age at diagnosis in one cohort 8.7 months	Więcek & Paprocka 2024: https://doi.org/10.3390/metabo14010038; Fujisawa et al. 2022: https://doi.org/10.1016/j.ymgmr.2022.100849; Zhu et al. 2024: https://doi.org/10.1186/s12887-024-04885-x	(wiecek2024disordersofcopper pages 8-10, fujisawa2022earlyclinicalsigns pages 1-2, zhu2024brainandthe pages 1-2)
Prognosis / mortality	Natural history is progressive and often fatal in classic disease; respiratory and gastrointestinal complications are common causes of death; OHS and AMD have substantially better survival than CMD	Without treatment, most classic cases die by <3 years (some reviews state before 4 years); in 162-patient review CMD mortality 40.6%, mean age at death 2.3 years; OHS mortality 13.5%, mean age at death 25.3 years; cerebrovascular accidents reported in up to 10%	De Feyter et al. 2023: https://doi.org/10.1002/jimd.12590; Vairo et al. 2019: https://doi.org/10.1016/j.ymgme.2018.12.005; Więcek & Paprocka 2024: https://doi.org/10.3390/metabo14010038	(feyter2023atp7a‐relatedcoppertransport pages 18-21, wiecek2024disordersofcopper pages 10-11, wiecek2024disordersofcopper pages 8-10, vairo2019asystematicreview pages 1-6, feyter2023atp7a‐relatedcoppertransport pages 24-27)
Treatment-linked prognosis modifier	Early parenteral copper-histidine / copper histidinate is the main disease-modifying therapy; best outcomes occur with neonatal / presymptomatic initiation, especially when residual ATP7A activity remains	Early-treated survival in summarized cohorts: 62.5% vs 8.3–37.5% and 92% vs 13% versus later/historical comparators; one long-surviving treated patient reached 37 years; combined mouse therapy rAAV9-rsATP7A + CuHis achieved 53.3% long-term survival vs 0% with either alone	Vairo et al. 2019: https://doi.org/10.1016/j.ymgme.2018.12.005; Tümer et al. 2017: https://doi.org/10.1111/cge.13083; Haddad et al. 2018: https://doi.org/10.1016/j.omtm.2018.07.002	(haddad2018cerebrospinalfluiddirectedraav9rsatp7a pages 1-2, tumer2017a37‐year‐oldmenkes pages 1-4, vairo2019asystematicreview pages 1-6, fujisawa2022earlyclinicalsigns pages 1-2, vairo2019asystematicreview pages 10-14)

Table: This table compiles core disease metadata, subtype distinctions, diagnostic biomarkers, epidemiology, and prognosis for Menkes disease from the gathered evidence. It is designed as a compact reference for rapid knowledge-base population with direct citation support.

Notes on evidence gaps

ICD-10/ICD-11, MeSH, Orphanet, and MONDO identifiers were not extractable from the retrieved full-text set in this run and should be programmatically added from their respective terminologies/databases.
Treatment evidence in humans remains limited by small cohorts and historical comparisons; heterogeneity by residual ATP7A function is strongly suggested by long-term survivor case evidence. (tumer2017a37‐year‐oldmenkes pages 1-4, vairo2019asystematicreview pages 10-14)

References

(wiecek2024disordersofcopper pages 7-8): Sabina Więcek and Justyna Paprocka. Disorders of copper metabolism in children—a problem too rarely recognized. Metabolites, 14:38, Jan 2024. URL: https://doi.org/10.3390/metabo14010038, doi:10.3390/metabo14010038. This article has 18 citations.
(fujisawa2022earlyclinicalsigns pages 1-2): Chie Fujisawa, Hiroko Kodama, Yasuhiro Sato, Masakazu Mimaki, Mariko Yagi, Hiroyuki Awano, Muneaki Matsuo, Haruo Shintaku, Sayaka Yoshida, Masaki Takayanagi, Mitsuru Kubota, Akihito Takahashi, and Yoshikiyo Akasaka. Early clinical signs and treatment of menkes disease. Molecular Genetics and Metabolism Reports, 31:100849, Jun 2022. URL: https://doi.org/10.1016/j.ymgmr.2022.100849, doi:10.1016/j.ymgmr.2022.100849. This article has 48 citations.
(vairo2019asystematicreview pages 1-6): Filippo Pinto e Vairo, Bruna Cristine Chwal, Silvana Perini, Maria Angélica Pires Ferreira, Ana Carolina de Freitas Lopes, and Jonas Alex Morales Saute. A systematic review and evidence-based guideline for diagnosis and treatment of menkes disease. Molecular genetics and metabolism, 126 1:6-13, Jan 2019. URL: https://doi.org/10.1016/j.ymgme.2018.12.005, doi:10.1016/j.ymgme.2018.12.005. This article has 111 citations and is from a peer-reviewed journal.
(feyter2023atp7a‐relatedcoppertransport pages 14-18): S. De Feyter, A. Beyens, and B. Callewaert. atp7a‐related copper transport disorders: a systematic review and definition of the clinical subtypes. Journal of Inherited Metabolic Disease, 46:163-173, Feb 2023. URL: https://doi.org/10.1002/jimd.12590, doi:10.1002/jimd.12590. This article has 27 citations and is from a peer-reviewed journal.
(feyter2023atp7a‐relatedcoppertransport pages 18-21): S. De Feyter, A. Beyens, and B. Callewaert. atp7a‐related copper transport disorders: a systematic review and definition of the clinical subtypes. Journal of Inherited Metabolic Disease, 46:163-173, Feb 2023. URL: https://doi.org/10.1002/jimd.12590, doi:10.1002/jimd.12590. This article has 27 citations and is from a peer-reviewed journal.
(zhu2024brainandthe pages 1-2): Juncheng Zhu, Yi Liao, Xuesheng Li, Fenglin Jia, Xinmao Ma, and Haibo Qu. Brain and the whole-body bone imaging appearances in menkes disease: a case report and literature review. BMC Pediatrics, Jun 2024. URL: https://doi.org/10.1186/s12887-024-04885-x, doi:10.1186/s12887-024-04885-x. This article has 4 citations and is from a peer-reviewed journal.
(wiecek2024disordersofcopper pages 10-11): Sabina Więcek and Justyna Paprocka. Disorders of copper metabolism in children—a problem too rarely recognized. Metabolites, 14:38, Jan 2024. URL: https://doi.org/10.3390/metabo14010038, doi:10.3390/metabo14010038. This article has 18 citations.
(tumer2017a37‐year‐oldmenkes pages 1-4): Zeynep Tümer, M. Petris, S. Zhu, J. Mercer, J. Bukrinski, S. Bilz, Kurt Baerlocher, N. Horn, and Lisbeth Birk Møller. A 37‐year‐old menkes disease patient—residual atp7a activity and early copper administration as key factors in beneficial treatment. Clinical Genetics, 92:548-553, Nov 2017. URL: https://doi.org/10.1111/cge.13083, doi:10.1111/cge.13083. This article has 10 citations and is from a peer-reviewed journal.
(feyter2023atp7a‐relatedcoppertransport pages 24-27): S. De Feyter, A. Beyens, and B. Callewaert. atp7a‐related copper transport disorders: a systematic review and definition of the clinical subtypes. Journal of Inherited Metabolic Disease, 46:163-173, Feb 2023. URL: https://doi.org/10.1002/jimd.12590, doi:10.1002/jimd.12590. This article has 27 citations and is from a peer-reviewed journal.
(wiecek2024disordersofcopper pages 8-10): Sabina Więcek and Justyna Paprocka. Disorders of copper metabolism in children—a problem too rarely recognized. Metabolites, 14:38, Jan 2024. URL: https://doi.org/10.3390/metabo14010038, doi:10.3390/metabo14010038. This article has 18 citations.
(feyter2023atp7a‐relatedcoppertransport pages 1-5): S. De Feyter, A. Beyens, and B. Callewaert. atp7a‐related copper transport disorders: a systematic review and definition of the clinical subtypes. Journal of Inherited Metabolic Disease, 46:163-173, Feb 2023. URL: https://doi.org/10.1002/jimd.12590, doi:10.1002/jimd.12590. This article has 27 citations and is from a peer-reviewed journal.
(rozensztrauch2023healthrelatedqualityof pages 1-2): Anna Rozensztrauch, Izabela Dzien, and Robert Śmigiel. Health-related quality of life and family functioning of primary caregivers of children with menkes disease. Journal of Clinical Medicine, 12:1769, Feb 2023. URL: https://doi.org/10.3390/jcm12051769, doi:10.3390/jcm12051769. This article has 8 citations.
(rozensztrauch2023healthrelatedqualityof pages 7-8): Anna Rozensztrauch, Izabela Dzien, and Robert Śmigiel. Health-related quality of life and family functioning of primary caregivers of children with menkes disease. Journal of Clinical Medicine, 12:1769, Feb 2023. URL: https://doi.org/10.3390/jcm12051769, doi:10.3390/jcm12051769. This article has 8 citations.
(rozensztrauch2023healthrelatedqualityof pages 4-5): Anna Rozensztrauch, Izabela Dzien, and Robert Śmigiel. Health-related quality of life and family functioning of primary caregivers of children with menkes disease. Journal of Clinical Medicine, 12:1769, Feb 2023. URL: https://doi.org/10.3390/jcm12051769, doi:10.3390/jcm12051769. This article has 8 citations.
(vairo2019asystematicreview pages 6-10): Filippo Pinto e Vairo, Bruna Cristine Chwal, Silvana Perini, Maria Angélica Pires Ferreira, Ana Carolina de Freitas Lopes, and Jonas Alex Morales Saute. A systematic review and evidence-based guideline for diagnosis and treatment of menkes disease. Molecular genetics and metabolism, 126 1:6-13, Jan 2019. URL: https://doi.org/10.1016/j.ymgme.2018.12.005, doi:10.1016/j.ymgme.2018.12.005. This article has 111 citations and is from a peer-reviewed journal.
(vairo2019asystematicreview pages 18-22): Filippo Pinto e Vairo, Bruna Cristine Chwal, Silvana Perini, Maria Angélica Pires Ferreira, Ana Carolina de Freitas Lopes, and Jonas Alex Morales Saute. A systematic review and evidence-based guideline for diagnosis and treatment of menkes disease. Molecular genetics and metabolism, 126 1:6-13, Jan 2019. URL: https://doi.org/10.1016/j.ymgme.2018.12.005, doi:10.1016/j.ymgme.2018.12.005. This article has 111 citations and is from a peer-reviewed journal.
(zhu2024brainandthe media f56ccfea): Juncheng Zhu, Yi Liao, Xuesheng Li, Fenglin Jia, Xinmao Ma, and Haibo Qu. Brain and the whole-body bone imaging appearances in menkes disease: a case report and literature review. BMC Pediatrics, Jun 2024. URL: https://doi.org/10.1186/s12887-024-04885-x, doi:10.1186/s12887-024-04885-x. This article has 4 citations and is from a peer-reviewed journal.
(zhu2024brainandthe media f2ce26df): Juncheng Zhu, Yi Liao, Xuesheng Li, Fenglin Jia, Xinmao Ma, and Haibo Qu. Brain and the whole-body bone imaging appearances in menkes disease: a case report and literature review. BMC Pediatrics, Jun 2024. URL: https://doi.org/10.1186/s12887-024-04885-x, doi:10.1186/s12887-024-04885-x. This article has 4 citations and is from a peer-reviewed journal.
(vairo2019asystematicreview pages 10-14): Filippo Pinto e Vairo, Bruna Cristine Chwal, Silvana Perini, Maria Angélica Pires Ferreira, Ana Carolina de Freitas Lopes, and Jonas Alex Morales Saute. A systematic review and evidence-based guideline for diagnosis and treatment of menkes disease. Molecular genetics and metabolism, 126 1:6-13, Jan 2019. URL: https://doi.org/10.1016/j.ymgme.2018.12.005, doi:10.1016/j.ymgme.2018.12.005. This article has 111 citations and is from a peer-reviewed journal.
(zhu2024brainandthe pages 4-6): Juncheng Zhu, Yi Liao, Xuesheng Li, Fenglin Jia, Xinmao Ma, and Haibo Qu. Brain and the whole-body bone imaging appearances in menkes disease: a case report and literature review. BMC Pediatrics, Jun 2024. URL: https://doi.org/10.1186/s12887-024-04885-x, doi:10.1186/s12887-024-04885-x. This article has 4 citations and is from a peer-reviewed journal.
(haddad2018cerebrospinalfluiddirectedraav9rsatp7a pages 1-2): Marie Reine Haddad, Eun-Young Choi, Patricia M. Zerfas, Ling Yi, Diego Martinelli, Patricia Sullivan, David S. Goldstein, Jose A. Centeno, Lauren R. Brinster, Martina Ralle, and Stephen G. Kaler. Cerebrospinal fluid-directed raav9-rsatp7a plus subcutaneous copper histidinate advance survival and outcomes in a menkes disease mouse model. Molecular Therapy - Methods & Clinical Development, 10:165-178, Sep 2018. URL: https://doi.org/10.1016/j.omtm.2018.07.002, doi:10.1016/j.omtm.2018.07.002. This article has 39 citations.
(NCT00001262 chunk 1): Copper Histidine Therapy for Menkes Diseases. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). 1990. ClinicalTrials.gov Identifier: NCT00001262
(NCT00811785 chunk 1): Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency. Cyprium Therapeutics, Inc.. 2009. ClinicalTrials.gov Identifier: NCT00811785
(NCT04074512 chunk 1): Copper Histidinate Treatment for Menkes Disease. Sentynl Therapeutics, Inc.. ClinicalTrials.gov Identifier: NCT04074512
(feyter2023atp7a‐relatedcoppertransport pages 27-31): S. De Feyter, A. Beyens, and B. Callewaert. atp7a‐related copper transport disorders: a systematic review and definition of the clinical subtypes. Journal of Inherited Metabolic Disease, 46:163-173, Feb 2023. URL: https://doi.org/10.1002/jimd.12590, doi:10.1002/jimd.12590. This article has 27 citations and is from a peer-reviewed journal.

Ask OpenScientist

OpenScientist Report

Classifications

Mappings

Inheritance

Subtypes

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Biochemical Markers

Diagnosis

Progression

Prevalence

Related Datasets

Clinical Trials

Animal Models

Source YAML

References & Deep Research

References

Deep Research

Menkes Disease (ATP7A-related copper transport disorder) — Comprehensive Disease Characteristics Report

1. Disease information

Overview (current understanding)

Key identifiers

Synonyms / alternative names

Evidence source type

2. Etiology

Disease causal factors

Risk factors

Protective factors

Gene–environment interactions

3. Phenotypes (clinical spectrum)

ATP7A-related clinical subtypes (2023 systematic re-definition)

Common phenotypes (type → characteristics → suggested HPO)

Quality of life impact (recent data)

4. Genetic / molecular information

Causal gene

Pathogenic variant classes and functional consequences

Modifier genes / epigenetics / chromosomal abnormalities

5. Environmental information

6. Mechanism / pathophysiology

Core causal chain (systemic copper deficiency → enzyme dysfunction → multisystem phenotype)

Upstream vs downstream mechanisms

Suggested ontology terms

7. Anatomical structures affected

Organ systems (supported)

Imaging-supported anatomical localization (UBERON suggestions)

8. Temporal development (onset and progression)

9. Inheritance and population

Inheritance

Epidemiology (recently cited estimates)

10. Diagnostics

Laboratory tests and biomarkers

Imaging

Genetic testing

Prenatal diagnosis and counseling

11. Outcome / prognosis

Natural history (untreated)

Subtype-stratified mortality (systematic review)

12. Treatment

Standard disease-modifying therapy: parenteral copper histidine / copper histidinate

Supportive care (real-world implementation)

Emerging/experimental therapies (latest research emphasis)

13. Prevention

14. Other species / natural disease

15. Model organisms

Current applications and real-world implementations (ClinicalTrials.gov)

Expert opinion / analysis (authoritative synthesis)

Reference summary table

Notes on evidence gaps